🏷

Classifications

ICD-O Morphology

Harrison's Part

📘

Definitions

1

Malignant ovarian germ cell tumor case definition

A malignant ovarian neoplasm derived from the ovarian germ cell lineage, encompassing the primitive germ cell tumors (dysgerminoma, yolk sac tumor, embryonal carcinoma, non-gestational choriocarcinoma, mixed germ cell tumor) and malignant (immature) teratoma, and excluding epithelial ovarian carcinoma and sex cord-stromal tumors.

CASE_DEFINITION Rare gynecologic oncology disease grouping

Show evidence (2 references)

PMID:37372675 SUPPORT Human Clinical

"Precursory germ cells of the ovary form the basis of GCT. They are histologically classified into primitive GCT, teratomas, and monodermal and somatic-type tumours associated with dermoid cysts."

Establishes the ovarian germ cell origin and the histologic classification framework used to scope this umbrella entry.

PMID:37372675 SUPPORT Human Clinical

"A primitive GCT can be either a yolk sac tumour (YST), dysgerminoma, or mixed germ cell neoplasm. Teratomas are either mature (benign) or immature (malignant)."

Supports the specific histologic membership of the malignant ovarian germ cell tumor category modeled in has_subtypes.

◆

Subtypes

6

Ovarian dysgerminoma MONDO:0003481

35-50% of malignant ovarian germ cell tumors

The ovarian counterpart of testicular seminoma and the most common malignant ovarian germ cell histology. Composed of undifferentiated germinoma-like cells that retain the pluripotency program (OCT3/4, NANOG, SALL4) and express KIT/CD117. LDH is the usual serum marker; a syncytiotrophoblastic minority can secrete beta-hCG. Dysgerminoma is bilateral in a minority of pure cases (about 4-15% across series) and is the most chemosensitive MOGCT histology. This is the arm of the MOGCT spectrum with no dedicated dismech entry, so its mechanism is curated in depth on this page.

Show evidence (1 reference)

PMID:21523721 SUPPORT Human Clinical

"Dysgerminoma, the ovarian counterpart of seminoma, is the most common type of malignant ovarian germ cell tumor."

Directly supports dysgerminoma as the most common malignant ovarian germ cell tumor histology and its equivalence to testicular seminoma.

Ovarian yolk sac tumor MONDO:0006344

Endodermal sinus tumor showing extraembryonic (yolk sac/primitive endoderm) differentiation, marked by alpha-fetoprotein secretion and Schiller-Duval bodies. Yolk sac histology is an adverse prognostic factor and all yolk sac tumors receive adjuvant chemotherapy outside carefully selected stage IA-IB marker-negative disease. Curated in depth in the dedicated dismech entries Yolk_Sac_Tumor and Malignant_Non_Dysgerminomatous_Germ_Cell_Tumor_Of_Ovary.

Show evidence (1 reference)

PMID:22448662 SUPPORT Human Clinical

"SALL4 and glypican-3 were strongly positive in 100 and 79.3%, respectively, of YSTs."

Documents the ovarian yolk sac tumor immunophenotype that distinguishes this subtype within a series of malignant ovarian germ cell tumors.

Ovarian immature teratoma MONDO:0018369

Malignant teratoma graded by the quantity of immature (usually neuroepithelial) tissue. It is the one MOGCT histology in which chromosome 12p gain is typically absent, and completely resected disease is frequently managed by surveillance alone rather than chemotherapy.

Show evidence (1 reference)

PMID:38544795 SUPPORT Human Clinical

"Ovarian immature teratoma (IT) is a rare neoplasm comprising ∼3% of ovarian cancers, occurring primarily in young females."

Supports ovarian immature teratoma as a distinct rare ovarian germ cell neoplasm of young patients.

Ovarian embryonal carcinoma MONDO:0003581

A very rare primitive MOGCT showing embryonic (epiblast-like) differentiation with OCT3/4, SALL4, SOX2, and CD30 expression. It is frequently hormone-producing (beta-hCG) and carries the worst survival of the MOGCT histotypes in SEER analyses.

Show evidence (1 reference)

PMID:33706324 SUPPORT Human Clinical

"Dysgerminoma patients had the most favorable outcomes, whereas EC patients had the worst survival."

Supports embryonal carcinoma as the MOGCT histotype with the poorest outcome and dysgerminoma as the most favorable.

Non-gestational ovarian choriocarcinoma MONDO:0004322

Extremely rare trophoblastic MOGCT that secretes large amounts of beta-hCG and may present with precocious puberty or abnormal uterine bleeding. Distinguishing it from gestational choriocarcinoma metastatic to the ovary can require genotyping.

Show evidence (1 reference)

PMID:40020991 SUPPORT Human Clinical

"Nongestational ovarian choriocarcinoma (NGOC) is extremely rare, particularly in the pediatric population."

Supports non-gestational ovarian choriocarcinoma as an extremely rare MOGCT subtype.

Mixed malignant ovarian germ cell tumor MONDO:0003710

A tumor containing two or more distinct malignant germ cell components. Serum marker pattern and management follow the composition and quantity of the components present. Curated in depth in the dedicated dismech entry Mixed_Germ_Cell_Tumor.

Show evidence (1 reference)

PMID:33142349 SUPPORT Human Clinical

"To describe the clinical and ultrasound characteristics of three types of rare malignant ovarian germ cell tumor: embryonal carcinoma, non-gestational choriocarcinoma and malignant mixed germ cell tumor."

Supports malignant mixed germ cell tumor as one of the recognized rare malignant ovarian germ cell tumor types.

⚙

Pathophysiology

13

Dysgenetic Gonad With Y-Chromosome Material

A minority of malignant ovarian germ cell tumors arise on an identifiable predisposing substrate: a dysgenetic (streak) gonad containing Y-chromosome material, as in 46,XY complete gonadal dysgenesis (Swyer syndrome) or Turner syndrome with Y mosaicism. Germ cells in a dysgenetic gonad fail to complete maturation and persist in an OCT3/4-positive pluripotent state; expression of gonadoblastoma-region Y genes (TSPY) in that setting marks cells that can progress through gonadoblastoma to invasive dysgerminoma. This is the basis for prophylactic gonadectomy in high-risk differences of sex development.

primordial germ cell CL:0000670

germ cell development GO:0007281 ⚠ ABNORMAL

ovary UBERON:0000992

Downstream

Primordial Germ Cell Transformation With Retained Pluripotency Immature, OCT3/4-positive germ cells trapped in a dysgenetic gonad are the substrate for malignant transformation.

Show evidence (3 references)

PMID:35935368 SUPPORT Human Clinical

"Patients with 46,XY complete gonadal dysgenesis (4/6; 66.7%) had the highest tumor occurrence rate."

Quantifies gonadal tumor risk in the highest-risk dysgenetic-gonad group that underlies this predisposing node.

PMID:35935368 SUPPORT Human Clinical

"Among 44 gonadal samples from these 22 patients, the following were identified: five gonadoblastomas, three dysgerminomas, and two Leydig cell tumors."

Documents the gonadoblastoma-to-dysgerminoma tumor spectrum that arises in dysgenetic gonads with Y-chromosome material.

PMID:35481403 SUPPORT Human Clinical

"With specific antibodies for OCT3/4 expression, we marked the pluripotent germ cell fraction being potential tumour precursor cells."

Supports persistent OCT3/4-positive pluripotent germ cells in dysgenetic gonads as the tumour precursor population.

Primordial Germ Cell Transformation With Retained Pluripotency

Malignant ovarian germ cell tumors derive from primordial germ cells that fail to complete normal oogenesis and instead retain an embryonic pluripotency program (OCT3/4, NANOG, SALL4). This retained stemness both permits survival outside the normal differentiation trajectory and supplies the capacity for subsequent multi-lineage (embryonic and extraembryonic) differentiation that generates the histologic diversity of the disease.

primordial germ cell CL:0000670

stem cell population maintenance GO:0019827 ↑ INCREASED germ cell development GO:0007281 ⚠ ABNORMAL

ovary UBERON:0000992

Downstream

Chromosome 12p Gain and Copy-Number-Driven Genome Imbalance The transformed pluripotent germ cell acquires the characteristic germ cell tumor cytogenetic lesion.

Divergent Germinomatous and Non-Germinomatous Differentiation Retained pluripotency permits divergent differentiation into the several MOGCT histologies.

Histology-Determining Epigenetic Reprogramming The developmental epigenetic reprogramming that primordial germ cells normally undergo is the substrate on which the histology-determining methylation state is set at transformation.

Show evidence (2 references)

PMID:33435376 SUPPORT Human Clinical

"The malignant ovarian GCTs (mOGCTs) are assumed to derive from primordial germ cells (PGCs) with inherited or somatically acquired alterations [2]."

Directly supports primordial germ cells as the inferred cell of origin for malignant ovarian germ cell tumors.

PMID:37954076 SUPPORT Human Clinical

"They share genetic features including KIT and RAS mutations, amplification of chromosome 12p, and expression of pluripotency markers (NANOG (Nanog homeobox), OCT3/4 (Octamer-binding transcription factor 3/4), and SAL4 (Spalt-like trascription factor 4))."

Documents retained pluripotency-factor expression together with the characteristic KIT/RAS and 12p alterations of germinomatous germ cell tumors.

Chromosome 12p Gain and Copy-Number-Driven Genome Imbalance

Rather than a high point-mutation burden, malignant germ cell tumors are driven principally by copy-number imbalance. Gain of the short arm of chromosome 12, frequently as isochromosome 12p, is the keystone cytogenetic lesion shared across postpubertal-type germ cell tumors of the ovary and testis. Pure immature teratoma is the notable exception in which 12p gain is typically absent, which is consistent with its distinct meiotic-error/parthenogenetic origin.

cell population proliferation GO:0008283 ↑ INCREASED

Downstream

KIT and RAS-PI3K Oncogenic Signaling Activation Copy-number-driven genome imbalance co-occurs with activating lesions in the KIT/RAS/PI3K mitogenic axis.

Show evidence (2 references)

PMID:21523721 SUPPORT Human Clinical

"Chromosome 12p anomalies were found in 82% of the dysgerminomas and did not correlate with KIT abnormalities."

Quantifies chromosome 12p anomalies in ovarian dysgerminoma and shows they are independent of KIT status.

PMID:40275685 SUPPORT Human Clinical

"The most frequent genetic alteration across all malignant ovarian germ cell tumors subtypes, except for pure immature teratomas, is a gain in chromosome 12p."

Supports 12p gain as the dominant recurrent alteration across MOGCT subtypes and its absence in pure immature teratoma.

KIT and RAS-PI3K Oncogenic Signaling Activation

The dominant recurrent oncogenic lesions of malignant ovarian germ cell tumors fall in the receptor tyrosine kinase and downstream mitogenic pathways. Activating KIT mutations (characteristically exon 17 codon 816) and KIT amplification are enriched in dysgerminoma, where KIT/CD117 protein is expressed in the large majority of tumors; KRAS mutations together with PIK3CA and AKT1 amplification cluster instead in yolk sac tumor. KIT mutation is associated with more advanced stage at presentation and defines the rationale for KIT-inhibitor trials in dysgerminoma.

KIT hgnc:6342 KRAS hgnc:6407 PIK3CA hgnc:8975

Kit signaling pathway GO:0038109 ↑ INCREASED cell surface receptor protein tyrosine kinase signaling pathway GO:0007169 ↑ INCREASED

Downstream

Constitutive Mitogenic Pathway Activation Activated KIT and RAS/PI3K lesions drive ligand-independent mitogenic signaling.

Show evidence (3 references)

PMID:21523721 SUPPORT Human Clinical

"KIT exon 17 codon 816 mutations and KIT amplification were each detected in 6 cases of dysgerminoma (27%); however, there was no correlation between these 2 factors."

Quantifies the frequency of activating KIT lesions in ovarian dysgerminoma.

PMID:21523721 SUPPORT Human Clinical

"KIT expression was detected in 87% of dysgerminomas."

Supports near-universal KIT/CD117 protein expression in ovarian dysgerminoma.

PMID:40275685 SUPPORT Human Clinical

"KIT mutations are commonly observed in ovarian dysgerminomas and KRAS mutations, along with PIK3CA and AKT1 amplifications, are frequently found in yolk sac tumors"

Supports the histology-specific partition of KIT versus KRAS/PI3K-AKT alterations across MOGCT subtypes.

Constitutive Mitogenic Pathway Activation

KIT, RAS, and PI3K-AKT lesions converge on chronic, ligand-independent flux through the RAS-MAPK and PI3K-AKT-mTOR cascades, sustaining proliferation and survival of the transformed germ cell independently of extrinsic growth-factor cues. This is the conserved hallmark-1 effector node that the disorder-specific KIT (dysgerminoma) and KRAS/PIK3CA/AKT1 (yolk sac tumor) drivers feed into.

Ras protein signal transduction GO:0007265 ↑ INCREASED ERK1 and ERK2 cascade GO:0070371 ↑ INCREASED phosphatidylinositol 3-kinase/protein kinase B signal transduction GO:0043491 ↑ INCREASED cell population proliferation GO:0008283 ↑ INCREASED

Downstream

Growth-Factor-Independent Germ Cell Proliferation Constitutive mitogenic signaling drives cell-cycle entry independent of external growth-factor cues.

Show evidence (2 references)

PMID:37954076 SUPPORT Human Clinical

"They share genetic features including KIT and RAS mutations, amplification of chromosome 12p, and expression of pluripotency markers (NANOG (Nanog homeobox), OCT3/4 (Octamer-binding transcription factor 3/4), and SAL4 (Spalt-like trascription factor 4))."

Support is partial: the review documents recurrent KIT and RAS lesions in dysgerminoma/seminoma, from which downstream constitutive MAPK/PI3K flux is inferred rather than directly measured in ovarian tumors in this source.

PMID:40275685 SUPPORT Human Clinical

"KIT mutations are commonly observed in ovarian dysgerminomas and KRAS mutations, along with PIK3CA and AKT1 amplifications, are frequently found in yolk sac tumors"

The PIK3CA/AKT1 amplifications and KRAS mutations named here are the genomic basis for constitutive PI3K-AKT and RAS-MAPK signaling; pathway activity itself is inferred, hence PARTIAL.

Growth-Factor-Independent Germ Cell Proliferation

Sustained KIT/RAS/PI3K signaling carries the transformed germ cell through the G1 restriction point into repeated rounds of division without the normal requirement for extrinsic growth factors. Clinically this autonomous proliferation is what makes MOGCT one of the fastest-growing ovarian neoplasms, with symptoms often developing over only weeks.

primordial germ cell CL:0000670

cell population proliferation GO:0008283 ↑ INCREASED

Downstream

Rapidly Expanding Unilateral Ovarian Mass Autonomous proliferation produces the characteristic large, fast-growing ovarian tumor.

Show evidence (2 references)

PMID:40275685 SUPPORT Human Clinical

"unilateral, large, and grow rapidly"

The source describes malignant ovarian germ cell tumors as typically unilateral, large, and rapidly growing; rapid autonomous growth is the clinical readout of growth-factor-independent proliferation.

PMID:33577182 SUPPORT Human Clinical

"The tumors, bilateral in 4% of the cases and with a mean tumor diameter of 13 cm"

Support is partial: the 13 cm mean diameter in a 140-case pure dysgerminoma series quantifies the tumor burden produced by autonomous proliferation, but the series does not measure proliferation directly.

Histology-Determining Epigenetic Reprogramming

Germ cells undergo complete epigenetic reprogramming during development, and the DNA-methylation state at which transformation arrests is a principal determinant of which histology results. An epigenome-wide study of 154 paediatric germ cell tumours identified 8,481 differentially methylated regions between histologies, and unsupervised clustering on those regions recovered four clusters corresponding to tumour histology rather than to age, anatomical location, sex or FFPE status. Germinomatous tumours (germinoma/seminoma/dysgerminoma) are globally hypomethylated relative to yolk sac tumour. This is the layer that the copy-number arm does not explain: 12p gain is shared across MOGCT histologies, so it cannot by itself account for the germinomatous versus non-germinomatous split, whereas the methylation state clusters by exactly that split.

primordial germ cell CL:0000670

epigenetic (DNA methylation) regulation of gene expression GO:0040029 ↕ DYSREGULATED

Downstream

Divergent Germinomatous and Non-Germinomatous Differentiation The methylation state at which the transformed germ cell arrests determines whether it follows the germinomatous or the non-germinomatous (embryonic/extraembryonic) differentiation programme.

Show evidence (3 references)

PMID:30287918 SUPPORT Human Clinical

"We identified 8,481 DMRs (FWER < 0.05). Unsupervised hierarchical clustering of individual probes within DMRs resulted in four high level clusters closely corresponding to tumour histology."

Establishes in 154 primary human paediatric germ cell tumours that methylation state partitions the tumours by histology, which is the claim this node makes.

PMID:30287918 SUPPORT Human Clinical

"Germinomas displayed lower levels of methylation across the DMRs relative to the other histologic subtypes."

Supports the specific germinomatous-hypomethylation direction that distinguishes the dysgerminoma arm from the non-germinomatous arm.

PMID:30287918 SUPPORT Human Clinical

"Abnormal DNA methylation may be important in germ cell tumour (GCT) aetiology, as germ cells undergo complete epigenetic reprogramming during development."

Gives the developmental rationale linking the primordial germ cell origin to epigenetic susceptibility. Marked PARTIAL because the source frames it as "may be important" rather than as an established causal claim.

Divergent Germinomatous and Non-Germinomatous Differentiation

The histologic diversity of MOGCT reflects which differentiation program the transformed pluripotent germ cell adopts. Cells that remain germinoma-like produce dysgerminoma (OCT3/4-, NANOG-, SALL4-, CD117-positive, AFP-negative); extraembryonic differentiation produces yolk sac tumor (SALL4-, glypican-3-, AFP-positive, OCT4-negative) and non-gestational choriocarcinoma; embryonic/somatic differentiation produces embryonal carcinoma and immature teratoma; simultaneous divergent differentiation produces mixed tumors. The resulting immunophenotype is what pathology uses to assign subtype.

cell differentiation GO:0030154 ⚠ ABNORMAL

Downstream

Lineage-Specific Tumor Marker Secretion Each differentiation program secretes a characteristic serum marker.

Rapidly Expanding Unilateral Ovarian Mass All differentiation programs converge on formation of a bulky ovarian tumor.

Peritoneal, Nodal, and Distant Dissemination Histology determines the dominant dissemination route (lymphatic for dysgerminoma, peritoneal for yolk sac tumor, haematogenous for choriocarcinoma).

Show evidence (2 references)

PMID:22448662 SUPPORT Human Clinical

"All dysgerminomas were positive for OCT4, whereas all YSTs and immature teratomas were negative."

Demonstrates that ovarian germ cell tumor subtypes are separated by divergent, lineage-specific differentiation programs detectable by immunophenotype.

PMID:33435376 SUPPORT Human Clinical

"The primitive GCTs are subdivided into the ovarian counterpart of the male testicular seminoma, dysgerminoma (DG), and non-DGs. The development of non-DGs is characterized by differentiation into cell histologies that mimic embryonic tissues (embryonal carcinoma (EC), teratoma) and..."

Directly describes the germinomatous versus embryonic/extraembryonic differentiation split modeled by this node.

Lineage-Specific Tumor Marker Secretion

Because each MOGCT histology recapitulates a different embryonic lineage, each secretes a different circulating marker: yolk sac differentiation produces alpha-fetoprotein, trophoblastic differentiation produces beta-hCG, and dysgerminoma releases lactate dehydrogenase in proportion to tumor burden. Embryonal carcinoma can produce either AFP or beta-hCG. This lineage-to-marker mapping makes serum markers simultaneously a subtype clue, a staging aid, and the principal response and relapse monitor.

ovary UBERON:0000992

Show evidence (2 references)

PMID:40275685 SUPPORT Human Clinical

"Serum tumor markers are critical for initial diagnosis and for monitoring the disease during and after treatment."

Supports the diagnostic and monitoring role of the lineage-specific serum markers modeled by this node.

PMID:40275685 SUPPORT Human Clinical

"Unlike other non-dysgerminomatous germ cell tumors, embryonal carcinoma is frequently associated with signs of hormone production, particularly human chorionic gonadotropin"

Documents histology-specific hormone production, the basis for lineage-specific marker secretion.

Rapidly Expanding Unilateral Ovarian Mass

MOGCTs typically form a large, solid or solid-cystic, unilateral ovarian mass that enlarges over only weeks. Mass effect and capsular stretch produce abdominal pain and distension, and the pedunculated bulky mass is prone to torsion or rupture, which can present as an acute abdomen. Rapid growth is also why most tumors become symptomatic - and therefore are detected - at an early FIGO stage.

cell population proliferation GO:0008283 ↑ INCREASED

ovary UBERON:0000992

Downstream

Peritoneal, Nodal, and Distant Dissemination Capsular rupture and continued growth allow spread beyond the ovary.

Exquisite Platinum Chemosensitivity The resulting tumor, however bulky, remains highly sensitive to platinum-based chemotherapy.

Show evidence (2 references)

PMID:40275685 SUPPORT Human Clinical

"Common presenting symptoms include abdominal pain and a palpable pelvic-abdominal mass. Acute abdominal pain due to tumor torsion or rupture is also not uncommon"

Directly supports the bulky unilateral mass and its torsion/rupture complications as the dominant local manifestation.

PMID:40275685 SUPPORT Human Clinical

"Early diagnosis is common due to the rapid tumor growth and symptoms such as abdominal pain and distension, leading to favorable prognoses when combined with the high chemosensitivity of platinum-based regimens."

Links rapid growth to early symptomatic presentation and favorable prognosis.

Peritoneal, Nodal, and Distant Dissemination

Spread beyond the ovary follows histology-specific routes: dysgerminoma has the highest risk of lymphatic (retroperitoneal nodal) metastasis, yolk sac tumor spreads peritoneally as hypervascular implants, and choriocarcinoma disseminates haematogenously to lung and liver. Capsular rupture and peritoneal spread are the imaging complications specifically sought at staging. Because the disease remains chemosensitive, even disseminated disease is usually curable, which is why radical cytoreduction is avoided.

peritoneum UBERON:0002358 lymph node UBERON:0000029

Downstream

Exquisite Platinum Chemosensitivity Disseminated germ cell tumor remains chemocurable, which is why dissemination does not mandate radical surgery.

Show evidence (3 references)

PMID:40275685 SUPPORT Human Clinical

"Dysgerminomas occasionally involve bilateral ovaries and adjacent structures, while yolk sac tumors may spread peritoneally, appearing as hypervascular implants on contrast-enhanced"

Documents the peritoneal dissemination route and its imaging appearance.

PMID:40275685 SUPPORT Human Clinical

"Among germ cell tumors, dysgerminomas have the highest risk of lymphatic metastases."

Documents the lymphatic dissemination route that is most pronounced in dysgerminoma.

PMID:40275685 SUPPORT Human Clinical

"choriocarcinomas often metastasize to the lungs and liver"

Documents the haematogenous dissemination route of the trophoblastic histology.

Exquisite Platinum Chemosensitivity

Germ cell tumors are among the most chemosensitive solid tumors. Their embryonic, pluripotency-associated apoptotic wiring and limited DNA-damage tolerance mean cisplatin-induced DNA adducts efficiently trigger apoptosis, so bleomycin/etoposide/cisplatin achieves survival above 90% even in advanced disease. This is the pathophysiologic reason mutilating surgery is avoided and fertility-sparing surgery is oncologically safe. The corollary is that the dominant unmet need is the platinum-resistant minority, especially relapsed yolk sac tumor, in which nucleotide-excision repair, stemness, and detoxification programs restore survival.

apoptotic process GO:0006915 ↑ INCREASED

Downstream

Platinum-Resistant Relapse A minority of tumors escape platinum-induced apoptosis and relapse, which is the dominant unmet need in this otherwise curable disease.

Show evidence (2 references)

PMID:37954076 SUPPORT Human Clinical

"Both histologies are exquisitely sensitive to platinum chemotherapy, and the combination of bleomycin, etoposide, and cisplatin (BEP) yields survival rates greater than 90%."

Directly supports the exquisite platinum sensitivity and the resulting survival benefit modeled by this node.

PMID:37954076 SUPPORT Human Clinical

"However, BEP causes significant, lifelong toxicity (cardiovascular, renal, respiratory, and neurological) in these young patients with an expectation of cure."

Documents the toxicity burden that motivates de-escalation and surveillance strategies in this highly curable disease.

Platinum-Resistant Relapse

The clinically decisive minority are the tumors that survive platinum. Most relapses occur in the first few years and are detected by rising serum markers or imaging change; recurrence after primary chemotherapy carries a substantially worse prognosis, and relapsed yolk sac tumor in particular is the principal unmet need. Management shifts to high-dose chemotherapy with stem-cell rescue, selected secondary cytoreduction, or radiotherapy. A distinct, non-malignant mimic is growing teratoma syndrome, in which masses enlarge during chemotherapy with normalized markers because a benign mature teratoma component is proliferating; that entity is chemoresistant by nature and is treated by resection alone.

apoptotic process GO:0006915 ↓ DECREASED

Show evidence (2 references)

PMID:40275685 SUPPORT Human Clinical

"Patients who experience a recurrence of malignant disease after primary chemotherapy for malignant ovarian germ cell tumors are associated with a poorer prognosis."

Directly supports post-chemotherapy relapse as an adverse-prognosis state distinct from the chemosensitive majority.

PMID:40275685 SUPPORT Human Clinical

"Growing teratoma syndrome is characterized by a rapid increase in tumor size during chemotherapy, despite normalized tumor markers, due to the proliferation of a benign mature teratoma component."

Documents the chemoresistant benign mimic that must be distinguished from true platinum-resistant relapse.

✶

Histopathology

4

Lymphocyte-Rich Fibrous Septa in Dysgerminoma

Dysgerminoma classically shows nests and sheets of uniform polygonal cells with clear cytoplasm separated by fibrous septa containing a conspicuous lymphocytic infiltrate - the ovarian mirror image of testicular seminoma.

Show evidence (2 references)

PMID:33577182 SUPPORT Human Clinical

"an alveolar pattern resulting from delicate fibrovascular septa (51%), diffuse (33%), macronodular (14%), insular (26%), cords (28%), solid tubular (17%), microspaces (sometimes simulating glands) (12%), follicle-like spaces (5%), prominent fibrous bands (65%), stromal edema (56%), stromal..."

A 140-case pure ovarian dysgerminoma series quantifying the defining morphology: a lymphocytic infiltrate in every case, with fibrovascular septa and prominent fibrous bands as the dominant architectural features.

PMID:33577182 SUPPORT Human Clinical

"prominent population of cells with pale to clear cytoplasm (73%)"

Quantifies the clear-cytoplasm cell population described in this finding.

Immature Neuroepithelium in Immature Teratoma

The diagnosis and grading of immature teratoma rest on the amount of primitive neuroepithelium, seen as immature tubules and rosettes.

Show evidence (1 reference)

PMID:40275685 SUPPORT Human Clinical

"The diagnosis of immature teratomas relies on the presence of immature or embryonic tissues, with neuroepithelium being the most common immature element."

Directly supports immature neuroepithelium as the defining and grade-determining histologic element of immature teratoma.

Schiller-Duval Bodies in Yolk Sac Tumor

Perivascular Schiller-Duval bodies are the classic histologic hallmark of the yolk sac tumor component.

Show evidence (1 reference)

PMID:40818404 SUPPORT Human Clinical

"Histopathologic analysis confirmed YST, supported by characteristic Schiller-Duval bodies and markedly elevated alpha-fetoprotein (AFP) levels."

Supports Schiller-Duval bodies as the characteristic diagnostic histologic feature of yolk sac tumor.

Germ Cell Tumor Immunophenotype

Immunohistochemistry assigns subtype. Dysgerminoma is OCT3/4-, SALL4-, PLAP-, D2-40-, NANOG- and CD117/KIT-positive; yolk sac tumor is SALL4-, glypican-3- and AFP-positive but OCT4-negative; embryonal carcinoma adds SOX2 and CD30; choriocarcinoma is beta-hCG-positive and OCT3/4-negative.

Show evidence (2 references)

PMID:22448662 SUPPORT Human Clinical

"All 27 dysgerminomas and all 31 YSTs showed CD117 expression, with only nine (29%) positively stained in immature teratomas."

Quantifies CD117/KIT immunoreactivity across ovarian germ cell tumor subtypes.

PMID:22448662 SUPPORT Human Clinical

"CD117 can be used as a diagnostic marker for dysgerminoma and YST. SALL4 is a more sensitive and specific marker for YSTs than glypican-3. SALL4 and OCT4 are useful in distinguishing YST from dysgerminoma."

Supports the immunohistochemical panel used to distinguish the malignant ovarian germ cell tumor subtypes.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

12

Digestive 2

Palpable Pelvic-Abdominal Mass FREQUENT HP:0031500

Show evidence (1 reference)

PMID:40275685 SUPPORT Human Clinical

"Common presenting symptoms include abdominal pain and a palpable pelvic-abdominal mass."

The source names a palpable pelvic-abdominal mass as a "common" presenting symptom, which maps to the FREQUENT band; no quantitative frequency is asserted here because the cited abstract gives none.

Abdominal Distension Abdominal distention HP:0003270

Show evidence (1 reference)

PMID:40275685 SUPPORT Human Clinical

"Early diagnosis is common due to the rapid tumor growth and symptoms such as abdominal pain and distension, leading to favorable prognoses when combined with the high chemosensitivity of platinum-based regimens."

Directly names abdominal distension among the presenting symptoms of malignant ovarian germ cell tumor.

Genitourinary 2

Primary Amenorrhea With Gonadal Dysgenesis VERY_RARE HP:0000786

Show evidence (1 reference)

PMID:35935368 SUPPORT Human Clinical

"pediatric and adolescent patients with DSD and the presence of the Y chromosome who had unambiguous female genitalia and underwent bilateral gonadectomy or gonadal biopsy were included in this study"

Support is partial: this cohort defines the phenotypically female DSD population in which dysgerminoma arises, but the abstract does not itself quantify amenorrhea.

Gonadal Dysgenesis VERY_RARE HP:0000133

Show evidence (1 reference)

PMID:35935368 SUPPORT Human Clinical

"Patients with 46,XY complete gonadal dysgenesis (4/6; 66.7%) had the highest tumor occurrence rate."

Directly ties gonadal dysgenesis to the highest observed rate of gonadal germ cell neoplasia.

Metabolism 1

Elevated Alpha-Fetoprotein Elevated circulating alpha-fetoprotein concentration HP:0006254

Show evidence (2 references)

PMID:22448662 SUPPORT Human Clinical

"SALL4 and glypican-3 were strongly positive in 100 and 79.3%, respectively, of YSTs."

Support is partial: this series documents the yolk sac tumor lineage phenotype by immunohistochemistry rather than measuring serum AFP directly.

PMID:27401840 SUPPORT Human Clinical

"Data on AFP were available to calculate an early AFP decline in 57 patients."

Confirms that serum AFP is routinely measurable and clinically tracked in ovarian yolk sac tumor.

Nervous System 1

Paraneoplastic Anti-NMDA Receptor Encephalitis VERY_RARE Encephalopathy HP:0001298

Scope caveat: the association is with ovarian teratoma broadly, and in the defining series the majority of associated tumors were MATURE (benign) cystic teratomas, which are explicitly out of scope for this malignant-tumor entry and are listed under differential_diagnoses. The phenotype is retained here, tagged to the Immature Teratoma subtype, because immature (malignant) teratomas also cause it and because finding the tumor changes oncologic management; the supporting evidence is therefore marked PARTIAL. Separately, HPO has no term for autoimmune or anti-NMDA receptor encephalitis, so this phenotype binds the closest available parent (HP:0001298 Encephalopathy) and carries the specific syndrome name in preferred_term.

Show evidence (2 references)

PMID:17262855 SUPPORT Human Clinical

"Eleven patients had teratoma of the ovary (six mature) and one a mature teratoma in the mediastinum; five of five tumors examined contained nervous tissue that strongly expressed NR2 subunits and reacted with patients' antibodies."

Establishes the mechanistic link between ovarian teratoma neural tissue and the anti-NMDAR autoantibody response. Support is PARTIAL for this entry because the snippet itself records that six of the eleven ovarian tumors were mature (benign) teratomas, which fall outside the malignant scope of this page.

PMID:17262855 SUPPORT Human Clinical

"Twelve women (14-44 years) developed prominent psychiatric symptoms, amnesia, seizures, frequent dyskinesias, autonomic dysfunction, and decreased level of consciousness often requiring ventilatory support."

Describes the encephalopathic syndrome captured by this phenotype; the preferred_term is deliberately more specific than the bound HPO term. PARTIAL for the same scope reason as the preceding item.

Constitutional 1

Abdominal or Pelvic Pain FREQUENT Abdominal pain HP:0002027

Show evidence (1 reference)

PMID:40275685 SUPPORT Human Clinical

"Common presenting symptoms include abdominal pain and a palpable pelvic-abdominal mass."

The source names abdominal pain as a "common" presenting symptom, which maps to the FREQUENT band; no quantitative frequency is asserted here because the cited abstract gives none.

Other 5

Ovarian Neoplasm HP:0100615

Show evidence (1 reference)

PMID:37372675 SUPPORT Human Clinical

"GCTs represent 2-5% of ovarian cancers, with a yearly incidence of 4:100,000, and they usually affect young women and adolescents."

Establishes that these are ovarian cancers (ovarian neoplasms) of young women and adolescents.

Acute Abdomen From Torsion or Rupture OCCASIONAL HP:0033400

Temporal: ACUTE

Show evidence (2 references)

PMID:40275685 SUPPORT Human Clinical

"Acute abdominal pain due to tumor torsion or rupture is also not uncommon"

Directly supports torsion or rupture as a not-uncommon acute presentation, consistent with the OCCASIONAL frequency band.

PMID:19189702 SUPPORT Human Clinical

"The most common torsioned malignant ovarian tumors were of germ cell origin, in both premenarchal and postmenarchal girls."

Supports germ cell tumors as the predominant malignant histology among torsioned ovarian masses in this age group.

Elevated Beta-Human Chorionic Gonadotropin Elevated circulating beta chorionic gonadotropin concentration HP:6000485

Show evidence (2 references)

PMID:40275685 SUPPORT Human Clinical

"Unlike other non-dysgerminomatous germ cell tumors, embryonal carcinoma is frequently associated with signs of hormone production, particularly human chorionic gonadotropin"

Supports beta-hCG production as a histology-linked laboratory feature of malignant ovarian germ cell tumors.

PMID:40020991 SUPPORT Human Clinical

"Laboratory tests revealed elevated estradiol, β-hCG, and CA125 levels, with suppressed luteinizing hormone and follicle-stimulating hormone."

Documents marked beta-hCG elevation in a non-gestational ovarian choriocarcinoma.

Elevated Lactate Dehydrogenase Increased circulating lactate dehydrogenase concentration HP:0025435

Show evidence (2 references)

PMID:34987988 SUPPORT Human Clinical

"Tumor markers namely AFP, βHCG, and LDH increased in all except the patients with immature teratoma."

Supports LDH as part of the routinely elevated serum marker panel in malignant ovarian germ cell tumor.

PMID:26458677 SUPPORT Human Clinical

"Serum tumour markers including lactate dehydrogenase (LDH), beta-subunit of human chorionic gonadotropin (B-hCG) and luteinizing hormone/follicular stimulating hormone (LH/FSH) were all normal."

Included as a counter-example: LDH is routinely measured but can be normal in early-stage dysgerminoma, so a negative marker panel does not exclude disease.

Precocious Puberty VERY_RARE HP:0000826

Show evidence (2 references)

PMID:40020991 SUPPORT Human Clinical

"A 7-year-old girl presented with early puberty and an abdominal mass."

Documents precocious puberty as a presenting feature of a hormone-producing malignant ovarian germ cell tumor.

PMID:40020991 SUPPORT Human Clinical

"Following tumor resection, her hormone levels normalized, and symptoms resolved."

Confirms the tumor-dependent (paraneoplastic-endocrine) nature of the precocious puberty.

🧬

Genetic Associations

5

Chromosome 12p Gain / Isochromosome 12p (Keystone somatic cytogenetic lesion of postpubertal-type malignant germ cell tumor; supports germ cell tumor classification in diagnostically ambiguous cases.)

relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (2 references)

PMID:21523721 SUPPORT Human Clinical

"Chromosome 12p anomalies were found in 82% of the dysgerminomas and did not correlate with KIT abnormalities."

Quantifies chromosome 12p abnormality frequency in ovarian dysgerminoma.

PMID:2302685 SUPPORT Human Clinical

"We have found one or more copies of i(12p) in an ovarian germ cell tumor, histologically a yolk sac tumor."

Documents isochromosome 12p in an ovarian germ cell tumor, extending the lesion beyond dysgerminoma.

KIT (Somatic oncogenic driver enriched in dysgerminoma; associated with advanced stage and proposed as a therapeutic target.)

Gene: KIT hgnc:6342 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (2 references)

PMID:21523721 SUPPORT Human Clinical

"KIT mutations occur in approximately one-third of cases of dysgerminomas and are associated with advanced stage at presentation. KIT is a potential therapeutic target for those dysgerminomas that have the mutation."

Directly supports KIT as a recurrent somatic driver in ovarian dysgerminoma with stage association and therapeutic relevance.

PMID:37954076 SUPPORT Human Clinical

"They share genetic features including KIT and RAS mutations, amplification of chromosome 12p, and expression of pluripotency markers (NANOG (Nanog homeobox), OCT3/4 (Octamer-binding transcription factor 3/4), and SAL4 (Spalt-like trascription factor 4))."

Confirms KIT mutation as a shared genetic feature of dysgerminoma and its testicular counterpart seminoma.

KRAS (Somatic oncogenic driver of the RAS-MAPK arm in non-dysgerminomatous MOGCT.)

Gene: KRAS hgnc:6407 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (2 references)

PMID:40275685 SUPPORT Human Clinical

"KIT mutations are commonly observed in ovarian dysgerminomas and KRAS mutations, along with PIK3CA and AKT1 amplifications, are frequently found in yolk sac tumors"

Supports KRAS mutation as a recurrent somatic alteration in ovarian yolk sac tumor.

PMID:33435376 SUPPORT Human Clinical

"A subset of three patients (33.3% of all patients) harbored targetable oncogenic mutations in KRAS, KIT, ARID1A."

Molecular profiling series documenting targetable KRAS alterations in ovarian yolk sac tumor.

PIK3CA (Somatic alteration of the PI3K-AKT arm.)

Gene: PIK3CA hgnc:8975 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (1 reference)

PMID:38733954 SUPPORT Human Clinical

"For the 8 persistent and recurrent OYST: cancer driver genes including ANKRD36, ANKRD62, DNAH8, MUC5B, NUP205, RYR2, STARD9, MUC16, TTN, ARID1A and PIK3CA were frequently mutated; cell cycle, ABC transporters, HR, NHEJ and AMPK signal pathway demonstrated as the most significantly enriched..."

Supports recurrent PIK3CA alteration in persistent and recurrent ovarian yolk sac tumor.

Y-Chromosome Material in a Dysgenetic Gonad (Strongest recognized predisposing constitutional factor for malignant ovarian germ cell tumor, acting through gonadoblastoma; underpins the recommendation for prophylactic gonadectomy in high-risk syndromes.)

relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE

Show evidence (3 references)

PMID:35935368 SUPPORT Human Clinical

"Gonadal neoplasia was confirmed in six (27.3%) cases by pathological examination of surgical gonadal tissue samples."

Quantifies gonadal neoplasia risk in phenotypically female patients with DSD and Y-chromosome material.

PMID:39577758 SUPPORT Human Clinical

"Our data shows a prevalence of 24.6% of gonadal tumors in individuals with TS +Y and a relatively low risk of malignant transformation (3.5%)."

Provides the contrasting, lower malignant-transformation risk in Turner syndrome with Y mosaicism, refining the risk gradient across DSD groups.

PMID:39577758 SUPPORT Human Clinical

"Fourteen (29.8%) had gonadoblastoma. Two (4.3%) had dysgerminoma."

Documents the gonadoblastoma-to-dysgerminoma progression pathway in this predisposed population.

💊

Medical Actions

9

Fertility-Sparing Surgery

Action: unilateral salpingo-oophorectomy Ontology label: Unilateral Salpingo-oophorectomy NCIT:C94469

Unilateral salpingo-oophorectomy with minimal surgical staging is the standard primary treatment for adolescents and young adults, preserving the contralateral ovary and uterus. Because germ cell tumors are highly chemosensitive, extensive or mutilating cytoreduction is avoided.

Mechanism Target:

INHIBITS Rapidly Expanding Unilateral Ovarian Mass — Resection removes the tumor-bearing ovary while preserving reproductive potential.

Show evidence (2 references)

PMID:41001186 SUPPORT Human Clinical

"Fertility-sparing surgery, including unilateral salpingo-oophorectomy with minimal staging, is recommended for adolescent and young adult patients."

Directly supports fertility-sparing unilateral salpingo-oophorectomy as the recommended surgical approach.

PMID:40275685 SUPPORT Human Clinical

"Fertility-sparing surgery is the cornerstone of treatment for stage I disease, often followed by close surveillance to minimize the long-term toxicities of chemotherapy."

Supports fertility-sparing surgery as the cornerstone of stage I management.

BEP Chemotherapy

Action: chemotherapy Ontology label: Chemotherapy NCIT:C15632 Regimen: BEP regimen Ontology label: BEP Regimen NCIT:C63488

Agent: bleomycin CHEBI:22907 etoposide CHEBI:4911 cisplatin CHEBI:27899

Bleomycin, etoposide, and cisplatin is the standard first-line regimen for higher-risk stage I and for stage II-IV malignant ovarian germ cell tumors, typically for 3-4 cycles. Bleomycin is generally omitted after 3 cycles because of cumulative pulmonary toxicity, and it should be avoided in patients with pre-existing pulmonary disease and in those over 40 years old.

Mechanism Target:

MODULATES Exquisite Platinum Chemosensitivity — Cisplatin-induced DNA adducts exploit the intrinsic apoptotic sensitivity of germ cell tumors.

Show evidence (3 references)

PMID:41001186 SUPPORT Human Clinical

"The bleomycin/etoposide/cisplatin regimen remains the first-line therapy."

Directly supports BEP as first-line therapy for MOGCT.

PMID:37954076 SUPPORT Human Clinical

"Both histologies are exquisitely sensitive to platinum chemotherapy, and the combination of bleomycin, etoposide, and cisplatin (BEP) yields survival rates greater than 90%."

Quantifies the survival achieved with BEP in germinomatous germ cell tumors.

PMID:40275685 SUPPORT Human Clinical

"Due to the high pulmonary toxicity of bleomycin, it is generally omitted after 3 cycles, reaching a maximum total cumulative dose of 270 IU."

Supports the bleomycin cumulative-dose safety constraint described in the treatment description.

Risk-Adapted Active Surveillance

Completely resected, properly staged low-risk disease - stage IA dysgerminoma and stage IA grade 1 immature teratoma - is managed by surgery plus surveillance rather than adjuvant chemotherapy, because relapse is usually salvageable and chemotherapy carries substantial lifelong toxicity in this young population. Surveillance combines serial tumor markers with imaging, intensified during the first two years.

Show evidence (3 references)

PMID:40275685 SUPPORT Human Clinical

"According to the ESMO guidelines, Stage IA dysgerminomas and properly staged Stage IA Grade 1 immature teratomas should be treated with surgery alone, followed by postoperative surveillance."

Directly supports guideline-based surveillance-only management of low-risk stage IA disease.

PMID:41001186 SUPPORT Human Clinical

"Chemotherapy is not recommended for those with surgically resected immature teratomas."

Supports omission of adjuvant chemotherapy after complete resection of immature teratoma.

clinicaltrials:NCT03067181 SUPPORT Human Clinical

"This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed."

Prospective trial evaluating active surveillance in low-risk germ cell tumors, including ovarian primaries.

Carboplatin Substitution in Pediatric Patients

Action: chemotherapy Ontology label: Chemotherapy NCIT:C15632 Regimen: JEB regimen Ontology label: JEB Regimen NCIT:C67289

Agent: carboplatin CHEBI:31355 etoposide CHEBI:4911 bleomycin CHEBI:22907

Carboplatin may replace cisplatin in pediatric regimens (for example JEB) to reduce nephrotoxicity and ototoxicity while preserving the platinum backbone; the cisplatin-versus-carboplatin question in standard-risk disease is under randomized evaluation.

Mechanism Target:

MODULATES Exquisite Platinum Chemosensitivity — Carboplatin retains platinum-adduct-driven cytotoxicity with a different toxicity profile.

Show evidence (2 references)

PMID:40275685 SUPPORT Human Clinical

"For pediatric patients, carboplatin may be substituted for cisplatin"

Directly supports carboplatin substitution in the pediatric setting.

clinicaltrials:NCT03067181 SUPPORT Human Clinical

"The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors."

Randomized trial directly addressing the carboplatin-versus-cisplatin question in standard-risk germ cell tumors.

Paclitaxel-Carboplatin Chemotherapy

Action: chemotherapy Ontology label: Chemotherapy NCIT:C15632

Agent: paclitaxel CHEBI:45863 carboplatin CHEBI:31355

Paclitaxel plus carboplatin is under randomized evaluation as a less toxic alternative to BEP in fertility-preserving treatment of MOGCT; retrospective data suggest comparable safety and prognosis, but BEP remains standard.

Mechanism Target:

MODULATES Exquisite Platinum Chemosensitivity — Preserves platinum-driven cytotoxicity while substituting a taxane for bleomycin and etoposide.

Show evidence (1 reference)

PMID:36890292 SUPPORT Human Clinical

"The PC regimen is as safe as the BEP regimen for MOGCT patients with fertility preservation treatment, and no differences were observed in fertility and clinical prognosis."

Retrospective support only; prospective randomized confirmation is still pending, hence PARTIAL.

KIT-Directed Targeted Therapy

Action: Targeted Therapy NCIT:C93352

Agent: imatinib CHEBI:45783

KIT inhibition is a mechanistically motivated but so far experimental strategy for the roughly one-third of dysgerminomas that carry activating KIT mutations; reported clinical success has been limited.

Mechanism Target:

INHIBITS KIT and RAS-PI3K Oncogenic Signaling Activation — Small-molecule inhibition of the constitutively activated KIT receptor tyrosine kinase.

Show evidence (2 references)

PMID:40275685 SUPPORT Human Clinical

"Emerging targeted therapies and novel approaches, such as KIT inhibitors for dysgerminomas with KIT mutations, remain experimental, with limited success reported so far."

Support is partial and explicitly qualified: the strategy is biologically rational but has not yet demonstrated clinical benefit.

PMID:21523721 SUPPORT Human Clinical

"KIT is a potential therapeutic target for those dysgerminomas that have the mutation."

Provides the molecular rationale for KIT-directed therapy in mutated dysgerminoma.

Prophylactic Gonadectomy in High-Risk Gonadal Dysgenesis

Action: surgical procedure Ontology label: Surgical Procedure NCIT:C15329

Removal of dysgenetic gonads containing Y-chromosome material - most clearly indicated in confirmed 46,XY complete gonadal dysgenesis (Swyer syndrome) and considered in Turner syndrome with Y mosaicism - is the only established primary prevention for malignant ovarian germ cell tumor.

Mechanism Target:

INHIBITS Dysgenetic Gonad With Y-Chromosome Material — Removes the at-risk tissue before gonadoblastoma progresses to invasive dysgerminoma.

Show evidence (2 references)

PMID:35935368 SUPPORT Human Clinical

"Pediatric patients with 46,XY complete gonadal dysgenesis had a significantly increased risk of developing gonadal tumors and underwent prophylactic gonadectomy as soon as the diagnosis was confirmed"

Directly supports prophylactic gonadectomy in the highest-risk dysgenetic gonad group.

PMID:40275685 SUPPORT Human Clinical

"prophylactic gonadectomy may be a reasonable recommendation"

Supports prophylactic gonadectomy as a reasonable recommendation in high-risk syndromes such as Turner and Swyer syndrome.

High-Dose Chemotherapy With Autologous Stem-Cell Rescue

Action: autologous hematopoietic stem cell transplantation Ontology label: Autologous Hematopoietic Stem Cell Transplantation NCIT:C16039

For relapse after primary platinum-based chemotherapy, salvage options determined by a multidisciplinary team include high-dose chemotherapy with stem-cell rescue, further conventional chemotherapy, surgery, radiotherapy, or a combination. Evidence in ovarian primaries is largely extrapolated from testicular germ cell tumor.

Mechanism Target:

INHIBITS Platinum-Resistant Relapse — Dose intensification with haematopoietic rescue aims to overcome acquired platinum resistance at relapse.

Show evidence (1 reference)

PMID:40275685 SUPPORT Human Clinical

"High-dose chemotherapy with stem-cell transplantation offers promise in select cases, while the role of secondary cytoreductive surgery and radiotherapy is limited to specific indications."

Support is partial and explicitly hedged by the source: benefit is described as promising in selected cases rather than established.

Secondary Cytoreductive Surgery for Growing Teratoma Syndrome

Action: cytoreductive surgery Ontology label: Cytoreductive Surgery NCIT:C132068

Resection is the sole required treatment for growing teratoma syndrome - enlarging masses during chemotherapy with normalized tumor markers, driven by a proliferating benign mature teratoma component - and may also benefit selected recurrent immature teratoma and recurrent mixed malignant germ cell tumor. Routine secondary cytoreduction is otherwise of uncertain value in this chemosensitive disease.

Mechanism Target:

INHIBITS Platinum-Resistant Relapse — Surgery removes chemoresistant residual tissue that systemic therapy cannot eliminate.

Show evidence (2 references)

PMID:40275685 SUPPORT Human Clinical

"It appears that recurrent immature teratomas, growing teratoma syndrome, or recurrent mixed malignant germ cell tumors may benefit from cytoreductive surgery"

Names the specific recurrence settings in which secondary cytoreduction is indicated.

PMID:40275685 SUPPORT Human Clinical

"In these cases, surgery is the sole required treatment, aimed at alleviating compression symptoms and disease-related morbidity."

Establishes surgery as the definitive and sufficient treatment of growing teratoma syndrome.

🔬

Biochemical Markers

4

Alpha-Fetoprotein (Elevated in yolk sac tumor and in mixed tumors containing a yolk sac component; may also be elevated in embryonal carcinoma and immature teratoma.)

Show evidence (1 reference)

PMID:27401840 SUPPORT Human Clinical

"The serum AFP decline was calculated with the formula previously developed and validated in male patients with poor prognosis non-seminomatous germ cell tumors."

Supports serum AFP as a quantitative, kinetically interpreted biomarker in ovarian yolk sac tumor.

Beta-Human Chorionic Gonadotropin (Markedly elevated in non-gestational choriocarcinoma, frequently elevated in embryonal carcinoma, and elevated in the syncytiotrophoblast-containing minority of dysgerminomas.)

Show evidence (1 reference)

PMID:40020991 SUPPORT Human Clinical

"Laboratory tests revealed elevated estradiol, β-hCG, and CA125 levels, with suppressed luteinizing hormone and follicle-stimulating hormone."

Documents beta-hCG as the diagnostic serum biomarker in ovarian choriocarcinoma.

Lactate Dehydrogenase (Associated with dysgerminoma and generally proportional to tumor burden; can also rise in other MOGCT histologies.)

Show evidence (1 reference)

PMID:34987988 SUPPORT Human Clinical

"Tumor markers namely AFP, βHCG, and LDH increased in all except the patients with immature teratoma."

Supports LDH as a measured serum biomarker in malignant ovarian germ cell tumor evaluation.

Circulating miR-371a-3p (Emerging circulating biomarker overexpressed across malignant germ cell tumor sites and histologies (except pure teratoma); validated mainly in testicular germ cell tumor and still investigational in ovarian disease.)

Show evidence (1 reference)

PMID:38611057 SUPPORT Human Clinical

"Circulating levels of germ cell tumor (GCT)-associated miRNAs, such as miR-371a-3p, can be utilized as efficient and cost-effective alternatives in diagnosing and managing patients presenting with GCTs."

Support is partial because the validation evidence is germ-cell-tumor-broad (largely testicular) rather than ovarian-specific.

🔬

Diagnosis

3

Serum Tumor Marker Panel and Imaging Work-up

Initial evaluation of a rapidly enlarging adnexal mass in a young patient combines serum AFP, beta-hCG, and LDH with pelvic ultrasound and cross-sectional imaging (MRI preferred over CT in this young population) for characterization and staging.

diagnostic procedure NCIT:C18020

Show evidence (2 references)

PMID:40275685 SUPPORT Human Clinical

"Serum tumor markers are critical for initial diagnosis and for monitoring the disease during and after treatment."

Supports the central diagnostic and monitoring role of the serum marker panel.

PMID:40275685 SUPPORT Human Clinical

"Advanced imaging modalities like ultrasound, magnetic resonance imaging, and computed tomography are essential for staging, monitoring treatment response, and detecting recurrences."

Supports the imaging component of the diagnostic and surveillance work-up.

Histopathology With Immunohistochemistry

Definitive diagnosis and subtyping require histopathology with an immunohistochemical panel (SALL4, OCT3/4, PLAP, CD117/KIT, glypican-3, AFP, SOX2, CD30, beta-hCG) to separate the germ cell tumor subtypes from each other and from epithelial and sex cord-stromal ovarian neoplasms.

diagnostic procedure NCIT:C18020

Show evidence (2 references)

PMID:40275685 SUPPORT Human Clinical

"Pathology is pivotal for diagnosis, incorporating immunohistochemical markers to differentiate malignant ovarian germ cell tumors subtypes, including dysgerminomas, yolk sac tumors, and immature teratomas."

Directly supports immunohistochemistry-assisted histopathology as the definitive diagnostic modality.

PMID:40275685 SUPPORT Human Clinical

"Dysgerminoma is frequently positive for SALL4, OCT3/4, alkaline phosphatase, placental-like alkaline phosphatase (PLAP), D2-40, NANOG, and SCFR."

Specifies the dysgerminoma immunophenotype used in the diagnostic panel.

Karyotype in Premenarchal Presentation

Karyotyping is recommended in premenarchal girls presenting with a malignant ovarian germ cell tumor to detect an underlying dysgenetic gonad with Y-chromosome material, which changes management of the contralateral gonad.

karyotyping NCIT:C16768

Show evidence (1 reference)

PMID:40275685 SUPPORT Human Clinical

"A preoperative karyotype is ideally recommended for all premenarchal girls."

Directly supports preoperative karyotyping in premenarchal presentations.

📈

Progression

3

Adolescent and young adult presentation

Age: Childhood to young adulthood

Ovarian germ cell tumors are the leading gynecologic malignancy in patients younger than 25 years.

Show evidence (1 reference)

PMID:37820296 SUPPORT Human Clinical

"Testicular GCTs (TGCTs) are the most common cancers in 15- to 39-year-old men, and ovarian GCTs (OvGCTs) are the leading gynecologic malignancies in women younger than 25 years."

Supports the adolescent and young adult age distribution of ovarian germ cell tumors.

Rapid growth with early-stage detection

Because these tumors grow quickly and become symptomatic early, most are detected at an early FIGO stage, and survival tracks strongly with stage.

Show evidence (1 reference)

PMID:40275685 SUPPORT Human Clinical

"Survival rates are strongly correlated with International Federation of Gynecology and Obstetrics (FIGO) stage"

Establishes the stage dependence of outcome across the malignant ovarian germ cell tumor spectrum; the source reports 5-year overall survival of 91% for stage I versus 59% for stage IV.

Early relapse window

Recurrence is concentrated in the first two years after diagnosis, which determines the intensity of the post-treatment surveillance schedule.

Show evidence (1 reference)

PMID:40275685 SUPPORT Human Clinical

"Since approximately 75% of malignant ovarian germ cell tumors recurrences occur within the first 2 years after initial diagnosis"

Supports the front-loaded relapse risk that shapes surveillance intensity.

📊

Prevalence

2

Worldwide (women)

Annual Incidence 0.4 per 100,000 1–9 per 1,000,000

The source states a yearly incidence of "4:100,000" alongside the statement that malignant germ cell tumors make up 2-5% of ovarian cancers. That printed figure is internally inconsistent with the rest of the literature and with the age-specific pediatric rate curated below (5.7 per million at age 14, in the peak age band), so it is normalized here as 4 per 1,000,000 women per year (0.4 per 100,000). The verbatim source wording is retained in the snippet.

Show evidence (1 reference)

PMID:37372675 SUPPORT Human Clinical

"GCTs represent 2-5% of ovarian cancers, with a yearly incidence of 4:100,000, and they usually affect young women and adolescents."

Provides both the proportion among ovarian cancers and the reported annual incidence used for this record.

Girls aged 14 years

Annual Incidence 0.57 per 100,000 1–9 per 1,000,000

Approximately 5.7 cases per million among 14-year-old patients, rising further in the 15-19 year age band.

Show evidence (1 reference)

PMID:40275685 SUPPORT Human Clinical

"the incidence rate is approximately 5.7 cases per million among 14-year-old patients"

Gives the age-specific pediatric incidence used to populate this age-stratified record.

🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Malignant Germ Cell Tumor of Ovary:

Epithelial Ovarian Carcinoma Not Yet Curated MONDO:0005140

Overlapping Features The dominant ovarian malignancy overall, but typically in older patients, CA-125-driven rather than AFP/beta-hCG-driven, and biologically and therapeutically distinct from germ cell tumors.

Distinguishing Features

Older age at onset
Epithelial immunophenotype (PAX8, CK7) without germ cell markers (SALL4, OCT3/4, CD117)
Absence of chromosome 12p gain

Show evidence (1 reference)

PMID:40275685 SUPPORT Human Clinical

"Non-epithelial ovarian tumors constitute approximately 10% of all ovarian cancers, with malignant ovarian germ cell tumors accounting for about 5%"

Frames germ cell tumors as a small non-epithelial minority that must be distinguished from the far more common epithelial ovarian cancers.

Mature Cystic Teratoma Not Yet Curated MONDO:0003820

Overlapping Features The benign counterpart of immature teratoma (dermoid cyst); far more common and managed by cystectomy alone.

Distinguishing Features

Absence of immature (usually neuroepithelial) tissue on thorough sampling
Normal serum tumor markers

Show evidence (1 reference)

PMID:40275685 SUPPORT Human Clinical

"The diagnosis of immature teratomas relies on the presence of immature or embryonic tissues, with neuroepithelium being the most common immature element."

Identifies the histologic criterion that separates immature (malignant) from mature (benign) teratoma.

Small Cell Carcinoma of the Ovary, Hypercalcemic Type Not Yet Curated MONDO:0004319

Overlapping Features A highly aggressive SMARCA4-deficient ovarian malignancy that also affects young women and can mimic dysgerminoma microscopically.

Distinguishing Features

Hypercalcemia and SMARCA4/BRG1 loss by immunohistochemistry
Absence of germ cell markers (SALL4, OCT3/4, CD117) and of a lymphocytic infiltrate
Markedly worse prognosis and platinum-refractory behaviour

Show evidence (1 reference)

PMID:33577182 SUPPORT Human Clinical

"certain tumors of very different nature being in the differential such as undifferentiated carcinoma not otherwise specified, small cell carcinoma of hypercalcemic type, and malignant lymphoma"

A 140-case dysgerminoma series naming small cell carcinoma of hypercalcemic type among the tumors that variant dysgerminoma morphology can mimic.

Malignant Lymphoma Involving the Ovary Not Yet Curated MONDO:0002227

Overlapping Features Ovarian involvement by lymphoma produces a diffuse population of discohesive cells that can be mistaken for dysgerminoma.

Distinguishing Features

CD45/lymphoid immunophenotype with absent SALL4, OCT3/4 and CD117
Absence of fibrovascular septa and of chromosome 12p gain

Show evidence (1 reference)

PMID:33577182 SUPPORT Human Clinical

"certain tumors of very different nature being in the differential such as undifferentiated carcinoma not otherwise specified, small cell carcinoma of hypercalcemic type, and malignant lymphoma"

The same dysgerminoma series names malignant lymphoma as a recognized diagnostic pitfall.

🔬

Clinical Trials

2

NCT03067181 PHASE_III RECRUITING

Pediatric and adult germ cell tumor trial (AGCT1531) combining active surveillance for low-risk disease with a randomized comparison of carboplatin- versus cisplatin-based chemotherapy for standard-risk metastatic disease. Directly relevant to both the de-escalation and the platinum-selection questions in malignant ovarian germ cell tumor.

Target Phenotypes: Ovarian neoplasm HP:0100615

Show evidence (1 reference)

clinicaltrials:NCT03067181 SUPPORT Human Clinical

"The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors."

Trial directly addresses platinum selection and treatment de-escalation across pediatric and adult germ cell tumors including ovarian primaries.

NCT02429687 PHASE_III RECRUITING

MOGCT-01, an ovarian-specific randomized phase III trial comparing paclitaxel/carboplatin with BEP after surgery in newly diagnosed malignant ovarian germ cell tumor.

Target Phenotypes: Ovarian neoplasm HP:0100615

Show evidence (1 reference)

clinicaltrials:NCT02429687 SUPPORT Human Clinical

"Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed malignant ovarian germ cell tumor patients after surgery."

Ovarian-specific randomized evaluation of a less toxic alternative to BEP.

{ }

Source YAML

click to show

name: Malignant Germ Cell Tumor of Ovary
creation_date: "2026-07-31T23:45:00Z"
category: Complex
categories:
- Gynecologic Cancer
- Germ Cell Neoplasm
- Solid Tumor
synonyms:
- malignant ovarian germ cell tumor
- malignant ovarian germ cell neoplasm
- ovarian germ cell cancer
- MOGCT
description: >-
  Malignant germ cell tumor of ovary (MOGCT) is the umbrella category of ovarian
  malignancies arising from the primordial germ cell lineage rather than from
  ovarian surface epithelium. It comprises dysgerminoma (the ovarian counterpart
  of testicular seminoma and the most common malignant histology), yolk sac
  (endodermal sinus) tumor, immature teratoma, embryonal carcinoma,
  non-gestational choriocarcinoma, and mixed malignant germ cell tumor. MOGCTs
  represent only 2-5% of ovarian cancers but are the leading gynecologic
  malignancy of children, adolescents, and young adults. Transformed germ cells
  retain a pluripotency program (OCT3/4, NANOG, SALL4) and typically carry
  chromosome 12p gain rather than a high point-mutation burden; KIT alterations
  are enriched in dysgerminoma while KRAS/PIK3CA/AKT1 changes cluster in yolk sac
  tumor. Tumors are usually large, unilateral, and fast-growing, presenting with
  abdominal pain and a pelvic-abdominal mass, sometimes with torsion or rupture,
  and secreting lineage-specific serum markers (AFP, beta-hCG, LDH). A dysgenetic
  gonad containing Y-chromosome material (46,XY complete gonadal dysgenesis,
  Turner syndrome with Y mosaicism) is the strongest recognized predisposition,
  usually via gonadoblastoma. Because germ cell tumors are exquisitely
  platinum-sensitive, fertility-sparing surgery with risk-adapted surveillance or
  bleomycin/etoposide/cisplatin (BEP) chemotherapy cures most patients.
disease_term:
  preferred_term: malignant germ cell tumor of ovary
  term:
    id: MONDO:0018171
    label: malignant germ cell tumor of ovary
parents:
- ovarian germ cell tumor
- malignant germ cell tumor
- gonadal germ cell tumor
classifications:
  icdo_morphology:
    classification_value: Embryonal Neoplasm
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY

definitions:
- name: Malignant ovarian germ cell tumor case definition
  definition_type: CASE_DEFINITION
  description: >-
    A malignant ovarian neoplasm derived from the ovarian germ cell lineage,
    encompassing the primitive germ cell tumors (dysgerminoma, yolk sac tumor,
    embryonal carcinoma, non-gestational choriocarcinoma, mixed germ cell tumor)
    and malignant (immature) teratoma, and excluding epithelial ovarian carcinoma
    and sex cord-stromal tumors.
  scope: Rare gynecologic oncology disease grouping
  evidence:
  - reference: PMID:37372675
    reference_title: "Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Precursory germ cells of the ovary form the basis of GCT. They are
      histologically classified into primitive GCT, teratomas, and monodermal
      and somatic-type tumours associated with dermoid cysts.
    explanation: >-
      Establishes the ovarian germ cell origin and the histologic classification
      framework used to scope this umbrella entry.
  - reference: PMID:37372675
    reference_title: "Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A primitive GCT can be either a yolk sac tumour (YST), dysgerminoma, or
      mixed germ cell neoplasm. Teratomas are either mature (benign) or
      immature (malignant).
    explanation: >-
      Supports the specific histologic membership of the malignant ovarian germ
      cell tumor category modeled in has_subtypes.

has_subtypes:
- name: Dysgerminoma
  display_name: Ovarian dysgerminoma
  subtype_frequency: "35-50% of malignant ovarian germ cell tumors"
  description: >-
    The ovarian counterpart of testicular seminoma and the most common malignant
    ovarian germ cell histology. Composed of undifferentiated germinoma-like
    cells that retain the pluripotency program (OCT3/4, NANOG, SALL4) and express
    KIT/CD117. LDH is the usual serum marker; a syncytiotrophoblastic minority
    can secrete beta-hCG. Dysgerminoma is bilateral in a minority of pure cases
    (about 4-15% across series) and is the most chemosensitive MOGCT histology. This is the arm of the MOGCT
    spectrum with no dedicated dismech entry, so its mechanism is curated in
    depth on this page.
  subtype_term:
    preferred_term: ovarian dysgerminoma
    term:
      id: MONDO:0003481
      label: dysgerminoma of ovary
  evidence:
  - reference: PMID:21523721
    reference_title: "KIT gene mutation and amplification in dysgerminoma of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dysgerminoma, the ovarian counterpart of seminoma, is the most common type
      of malignant ovarian germ cell tumor.
    explanation: >-
      Directly supports dysgerminoma as the most common malignant ovarian germ
      cell tumor histology and its equivalence to testicular seminoma.
- name: Yolk Sac Tumor
  display_name: Ovarian yolk sac tumor
  description: >-
    Endodermal sinus tumor showing extraembryonic (yolk sac/primitive endoderm)
    differentiation, marked by alpha-fetoprotein secretion and Schiller-Duval
    bodies. Yolk sac histology is an adverse prognostic factor and all yolk sac
    tumors receive adjuvant chemotherapy outside carefully selected stage IA-IB
    marker-negative disease. Curated in depth in the dedicated dismech entries
    Yolk_Sac_Tumor and
    Malignant_Non_Dysgerminomatous_Germ_Cell_Tumor_Of_Ovary.
  subtype_term:
    preferred_term: ovarian yolk sac tumor
    term:
      id: MONDO:0006344
      label: ovarian yolk sac tumor
  evidence:
  - reference: PMID:22448662
    reference_title: "Diagnostic utility of CD117, CD133, SALL4, OCT4, TCL1 and glypican-3 in malignant germ cell tumors of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SALL4 and glypican-3 were strongly positive in 100 and 79.3%,
      respectively, of YSTs.
    explanation: >-
      Documents the ovarian yolk sac tumor immunophenotype that distinguishes
      this subtype within a series of malignant ovarian germ cell tumors.
- name: Immature Teratoma
  display_name: Ovarian immature teratoma
  description: >-
    Malignant teratoma graded by the quantity of immature (usually
    neuroepithelial) tissue. It is the one MOGCT histology in which chromosome
    12p gain is typically absent, and completely resected disease is frequently
    managed by surveillance alone rather than chemotherapy.
  subtype_term:
    preferred_term: ovarian immature teratoma
    term:
      id: MONDO:0018369
      label: immature ovarian teratoma
  evidence:
  - reference: PMID:38544795
    reference_title: "Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Ovarian immature teratoma (IT) is a rare neoplasm comprising ∼3% of
      ovarian cancers, occurring primarily in young females.
    explanation: >-
      Supports ovarian immature teratoma as a distinct rare ovarian germ cell
      neoplasm of young patients.
- name: Embryonal Carcinoma
  display_name: Ovarian embryonal carcinoma
  description: >-
    A very rare primitive MOGCT showing embryonic (epiblast-like) differentiation
    with OCT3/4, SALL4, SOX2, and CD30 expression. It is frequently
    hormone-producing (beta-hCG) and carries the worst survival of the MOGCT
    histotypes in SEER analyses.
  subtype_term:
    preferred_term: ovarian embryonal carcinoma
    term:
      id: MONDO:0003581
      label: ovarian embryonal carcinoma
  evidence:
  - reference: PMID:33706324
    reference_title: "Clinicopathological Features, Prognostic Factors, Survival Trends, and Treatment of Malignant Ovarian Germ Cell Tumors: A SEER Database Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dysgerminoma patients had the most favorable outcomes, whereas EC patients
      had the worst survival.
    explanation: >-
      Supports embryonal carcinoma as the MOGCT histotype with the poorest
      outcome and dysgerminoma as the most favorable.
- name: Non-Gestational Choriocarcinoma
  display_name: Non-gestational ovarian choriocarcinoma
  description: >-
    Extremely rare trophoblastic MOGCT that secretes large amounts of beta-hCG
    and may present with precocious puberty or abnormal uterine bleeding.
    Distinguishing it from gestational choriocarcinoma metastatic to the ovary
    can require genotyping.
  subtype_term:
    preferred_term: non-gestational ovarian choriocarcinoma
    term:
      id: MONDO:0004322
      label: non-gestational ovarian choriocarcinoma
  evidence:
  - reference: PMID:40020991
    reference_title: "Nongestational Ovarian Choriocarcinoma with Precocious Puberty in a 7-Year-Old Girl: A Rare Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Nongestational ovarian choriocarcinoma (NGOC) is extremely rare,
      particularly in the pediatric population.
    explanation: >-
      Supports non-gestational ovarian choriocarcinoma as an extremely rare
      MOGCT subtype.
- name: Mixed Malignant Germ Cell Tumor
  display_name: Mixed malignant ovarian germ cell tumor
  description: >-
    A tumor containing two or more distinct malignant germ cell components. Serum
    marker pattern and management follow the composition and quantity of the
    components present. Curated in depth in the dedicated dismech entry
    Mixed_Germ_Cell_Tumor.
  subtype_term:
    preferred_term: ovarian mixed germ cell neoplasm
    term:
      id: MONDO:0003710
      label: ovarian mixed germ cell neoplasm
  evidence:
  - reference: PMID:33142349
    reference_title: "Imaging in gynecological disease (22): clinical and ultrasound characteristics of ovarian embryonal carcinomas, non-gestational choriocarcinomas and malignant mixed germ cell tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To describe the clinical and ultrasound characteristics of three types of
      rare malignant ovarian germ cell tumor: embryonal carcinoma,
      non-gestational choriocarcinoma and malignant mixed germ cell tumor.
    explanation: >-
      Supports malignant mixed germ cell tumor as one of the recognized rare
      malignant ovarian germ cell tumor types.

prevalence:
- population: Worldwide (women)
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BAND_1_9_PER_1000000
  rate_per_100000: 0.4
  notes: >-
    The source states a yearly incidence of "4:100,000" alongside the statement
    that malignant germ cell tumors make up 2-5% of ovarian cancers. That
    printed figure is internally inconsistent with the rest of the literature
    and with the age-specific pediatric rate curated below (5.7 per million at
    age 14, in the peak age band), so it is normalized here as 4 per 1,000,000
    women per year (0.4 per 100,000). The verbatim source wording is retained in
    the snippet.
  evidence:
  - reference: PMID:37372675
    reference_title: "Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GCTs represent 2-5% of ovarian cancers, with a yearly incidence of
      4:100,000, and they usually affect young women and adolescents.
    explanation: >-
      Provides both the proportion among ovarian cancers and the reported annual
      incidence used for this record.
- population: Girls aged 14 years
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BAND_1_9_PER_1000000
  rate_per_100000: 0.57
  notes: >-
    Approximately 5.7 cases per million among 14-year-old patients, rising
    further in the 15-19 year age band.
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the incidence rate is approximately 5.7 cases per million among 14-year-old
      patients
    explanation: >-
      Gives the age-specific pediatric incidence used to populate this
      age-stratified record.

progression:
- phase: Adolescent and young adult presentation
  age_range: Childhood to young adulthood
  notes: >-
    Ovarian germ cell tumors are the leading gynecologic malignancy in patients
    younger than 25 years.
  evidence:
  - reference: PMID:37820296
    reference_title: "Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Testicular GCTs (TGCTs) are the most common cancers in 15- to 39-year-old
      men, and ovarian GCTs (OvGCTs) are the leading gynecologic malignancies in
      women younger than 25 years.
    explanation: >-
      Supports the adolescent and young adult age distribution of ovarian germ
      cell tumors.
- phase: Rapid growth with early-stage detection
  notes: >-
    Because these tumors grow quickly and become symptomatic early, most are
    detected at an early FIGO stage, and survival tracks strongly with stage.
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Survival rates are strongly correlated with International Federation of
      Gynecology and Obstetrics (FIGO) stage
    explanation: >-
      Establishes the stage dependence of outcome across the malignant ovarian
      germ cell tumor spectrum; the source reports 5-year overall survival of
      91% for stage I versus 59% for stage IV.
- phase: Early relapse window
  notes: >-
    Recurrence is concentrated in the first two years after diagnosis, which
    determines the intensity of the post-treatment surveillance schedule.
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Since approximately 75% of malignant ovarian germ cell tumors recurrences
      occur within the first 2 years after initial diagnosis
    explanation: >-
      Supports the front-loaded relapse risk that shapes surveillance intensity.

pathophysiology:
- name: Dysgenetic Gonad With Y-Chromosome Material
  biological_scale: TISSUE
  role: trigger
  description: >-
    A minority of malignant ovarian germ cell tumors arise on an identifiable
    predisposing substrate: a dysgenetic (streak) gonad containing Y-chromosome
    material, as in 46,XY complete gonadal dysgenesis (Swyer syndrome) or Turner
    syndrome with Y mosaicism. Germ cells in a dysgenetic gonad fail to complete
    maturation and persist in an OCT3/4-positive pluripotent state; expression of
    gonadoblastoma-region Y genes (TSPY) in that setting marks cells that can
    progress through gonadoblastoma to invasive dysgerminoma. This is the basis
    for prophylactic gonadectomy in high-risk differences of sex development.
  locations:
  - preferred_term: ovary
    term:
      id: UBERON:0000992
      label: ovary
  cell_types:
  - preferred_term: primordial germ cell
    term:
      id: CL:0000670
      label: primordial germ cell
  biological_processes:
  - preferred_term: germ cell development
    modifier: ABNORMAL
    term:
      id: GO:0007281
      label: germ cell development
  evidence:
  - reference: PMID:35935368
    reference_title: "Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and Y chromosomal constitution with different genetic etiologies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with 46,XY complete gonadal dysgenesis (4/6; 66.7%) had the
      highest tumor occurrence rate.
    explanation: >-
      Quantifies gonadal tumor risk in the highest-risk dysgenetic-gonad group
      that underlies this predisposing node.
  - reference: PMID:35935368
    reference_title: "Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and Y chromosomal constitution with different genetic etiologies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among 44 gonadal samples from these 22 patients, the following were
      identified: five gonadoblastomas, three dysgerminomas, and two Leydig cell
      tumors.
    explanation: >-
      Documents the gonadoblastoma-to-dysgerminoma tumor spectrum that arises in
      dysgenetic gonads with Y-chromosome material.
  - reference: PMID:35481403
    reference_title: "Sex chromosome DSD individuals with mosaic 45,X0 and aberrant Y chromosomes in 46,XY cells: distinct gender phenotypes and germ cell tumour risks."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      With specific antibodies for OCT3/4 expression, we marked the pluripotent
      germ cell fraction being potential tumour precursor cells.
    explanation: >-
      Supports persistent OCT3/4-positive pluripotent germ cells in dysgenetic
      gonads as the tumour precursor population.
  downstream:
  - target: Primordial Germ Cell Transformation With Retained Pluripotency
    description: >-
      Immature, OCT3/4-positive germ cells trapped in a dysgenetic gonad are the
      substrate for malignant transformation.

- name: Primordial Germ Cell Transformation With Retained Pluripotency
  biological_scale: CELLULAR
  role: driver
  description: >-
    Malignant ovarian germ cell tumors derive from primordial germ cells that
    fail to complete normal oogenesis and instead retain an embryonic pluripotency
    program (OCT3/4, NANOG, SALL4). This retained stemness both permits survival
    outside the normal differentiation trajectory and supplies the capacity for
    subsequent multi-lineage (embryonic and extraembryonic) differentiation that
    generates the histologic diversity of the disease.
  cell_types:
  - preferred_term: primordial germ cell
    term:
      id: CL:0000670
      label: primordial germ cell
  locations:
  - preferred_term: ovary
    term:
      id: UBERON:0000992
      label: ovary
  biological_processes:
  - preferred_term: stem cell population maintenance
    modifier: INCREASED
    term:
      id: GO:0019827
      label: stem cell population maintenance
  - preferred_term: germ cell development
    modifier: ABNORMAL
    term:
      id: GO:0007281
      label: germ cell development
  evidence:
  - reference: PMID:33435376
    reference_title: "Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The malignant ovarian GCTs (mOGCTs) are assumed to derive from primordial
      germ cells (PGCs) with inherited or somatically acquired alterations [2].
    explanation: >-
      Directly supports primordial germ cells as the inferred cell of origin for
      malignant ovarian germ cell tumors.
  - reference: PMID:37954076
    reference_title: "Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They share genetic features including KIT and RAS mutations, amplification
      of chromosome 12p, and expression of pluripotency markers (NANOG (Nanog
      homeobox), OCT3/4 (Octamer-binding transcription factor 3/4), and SAL4
      (Spalt-like trascription factor 4)).
    explanation: >-
      Documents retained pluripotency-factor expression together with the
      characteristic KIT/RAS and 12p alterations of germinomatous germ cell
      tumors.
  downstream:
  - target: Chromosome 12p Gain and Copy-Number-Driven Genome Imbalance
    description: >-
      The transformed pluripotent germ cell acquires the characteristic germ cell
      tumor cytogenetic lesion.
  - target: Divergent Germinomatous and Non-Germinomatous Differentiation
    description: >-
      Retained pluripotency permits divergent differentiation into the several
      MOGCT histologies.
  - target: Histology-Determining Epigenetic Reprogramming
    description: >-
      The developmental epigenetic reprogramming that primordial germ cells
      normally undergo is the substrate on which the histology-determining
      methylation state is set at transformation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES

- name: Chromosome 12p Gain and Copy-Number-Driven Genome Imbalance
  biological_scale: MOLECULAR
  role: driver
  description: >-
    Rather than a high point-mutation burden, malignant germ cell tumors are
    driven principally by copy-number imbalance. Gain of the short arm of
    chromosome 12, frequently as isochromosome 12p, is the keystone cytogenetic
    lesion shared across postpubertal-type germ cell tumors of the ovary and
    testis. Pure immature teratoma is the notable exception in which 12p gain is
    typically absent, which is consistent with its distinct
    meiotic-error/parthenogenetic origin.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:21523721
    reference_title: "KIT gene mutation and amplification in dysgerminoma of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Chromosome 12p anomalies were found in 82% of the dysgerminomas and did
      not correlate with KIT abnormalities.
    explanation: >-
      Quantifies chromosome 12p anomalies in ovarian dysgerminoma and shows they
      are independent of KIT status.
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most frequent genetic alteration across all malignant ovarian germ cell
      tumors subtypes, except for pure immature teratomas, is a gain in chromosome
      12p.
    explanation: >-
      Supports 12p gain as the dominant recurrent alteration across MOGCT
      subtypes and its absence in pure immature teratoma.
  downstream:
  - target: KIT and RAS-PI3K Oncogenic Signaling Activation
    description: >-
      Copy-number-driven genome imbalance co-occurs with activating lesions in
      the KIT/RAS/PI3K mitogenic axis.

- name: KIT and RAS-PI3K Oncogenic Signaling Activation
  biological_scale: MOLECULAR
  role: driver
  conforms_to: "sustaining_proliferative_signaling#Oncogenic Growth-Signal Lesion"
  description: >-
    The dominant recurrent oncogenic lesions of malignant ovarian germ cell tumors
    fall in the receptor tyrosine kinase and downstream mitogenic pathways.
    Activating KIT mutations (characteristically exon 17 codon 816) and KIT
    amplification are enriched in dysgerminoma, where KIT/CD117 protein is
    expressed in the large majority of tumors; KRAS mutations together with PIK3CA
    and AKT1 amplification cluster instead in yolk sac tumor. KIT mutation is
    associated with more advanced stage at presentation and defines the rationale
    for KIT-inhibitor trials in dysgerminoma.
  genes:
  - preferred_term: KIT
    term:
      id: hgnc:6342
      label: KIT
  - preferred_term: KRAS
    term:
      id: hgnc:6407
      label: KRAS
  - preferred_term: PIK3CA
    term:
      id: hgnc:8975
      label: PIK3CA
  biological_processes:
  - preferred_term: Kit signaling pathway
    modifier: INCREASED
    term:
      id: GO:0038109
      label: Kit signaling pathway
  - preferred_term: cell surface receptor protein tyrosine kinase signaling pathway
    modifier: INCREASED
    term:
      id: GO:0007169
      label: cell surface receptor protein tyrosine kinase signaling pathway
  evidence:
  - reference: PMID:21523721
    reference_title: "KIT gene mutation and amplification in dysgerminoma of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      KIT exon 17 codon 816 mutations and KIT amplification were each detected in
      6 cases of dysgerminoma (27%); however, there was no correlation between
      these 2 factors.
    explanation: >-
      Quantifies the frequency of activating KIT lesions in ovarian dysgerminoma.
  - reference: PMID:21523721
    reference_title: "KIT gene mutation and amplification in dysgerminoma of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      KIT expression was detected in 87% of dysgerminomas.
    explanation: >-
      Supports near-universal KIT/CD117 protein expression in ovarian
      dysgerminoma.
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      KIT mutations are commonly observed in ovarian dysgerminomas and KRAS
      mutations, along with PIK3CA and AKT1 amplifications, are frequently found
      in yolk sac tumors
    explanation: >-
      Supports the histology-specific partition of KIT versus KRAS/PI3K-AKT
      alterations across MOGCT subtypes.
  downstream:
  - target: Constitutive Mitogenic Pathway Activation
    description: >-
      Activated KIT and RAS/PI3K lesions drive ligand-independent mitogenic
      signaling.

- name: Constitutive Mitogenic Pathway Activation
  biological_scale: CELLULAR
  role: central_effector
  conforms_to: "sustaining_proliferative_signaling#Constitutive Mitogenic Pathway Activation"
  description: >-
    KIT, RAS, and PI3K-AKT lesions converge on chronic, ligand-independent flux
    through the RAS-MAPK and PI3K-AKT-mTOR cascades, sustaining proliferation and
    survival of the transformed germ cell independently of extrinsic
    growth-factor cues. This is the conserved hallmark-1 effector node that the
    disorder-specific KIT (dysgerminoma) and KRAS/PIK3CA/AKT1 (yolk sac tumor)
    drivers feed into.
  biological_processes:
  - preferred_term: Ras protein signal transduction
    modifier: INCREASED
    term:
      id: GO:0007265
      label: Ras protein signal transduction
  - preferred_term: ERK1 and ERK2 cascade
    modifier: INCREASED
    term:
      id: GO:0070371
      label: ERK1 and ERK2 cascade
  - preferred_term: phosphatidylinositol 3-kinase/protein kinase B signal transduction
    modifier: INCREASED
    term:
      id: GO:0043491
      label: phosphatidylinositol 3-kinase/protein kinase B signal transduction
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:37954076
    reference_title: "Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They share genetic features including KIT and RAS mutations, amplification
      of chromosome 12p, and expression of pluripotency markers (NANOG (Nanog
      homeobox), OCT3/4 (Octamer-binding transcription factor 3/4), and SAL4
      (Spalt-like trascription factor 4)).
    explanation: >-
      Support is partial: the review documents recurrent KIT and RAS lesions in
      dysgerminoma/seminoma, from which downstream constitutive MAPK/PI3K flux is
      inferred rather than directly measured in ovarian tumors in this source.
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      KIT mutations are commonly observed in ovarian dysgerminomas and KRAS
      mutations, along with PIK3CA and AKT1 amplifications, are frequently found
      in yolk sac tumors
    explanation: >-
      The PIK3CA/AKT1 amplifications and KRAS mutations named here are the
      genomic basis for constitutive PI3K-AKT and RAS-MAPK signaling; pathway
      activity itself is inferred, hence PARTIAL.
  downstream:
  - target: Growth-Factor-Independent Germ Cell Proliferation
    description: >-
      Constitutive mitogenic signaling drives cell-cycle entry independent of
      external growth-factor cues.

- name: Growth-Factor-Independent Germ Cell Proliferation
  biological_scale: CELLULAR
  role: consequence
  conforms_to: "sustaining_proliferative_signaling#Growth-Factor-Independent Proliferation"
  description: >-
    Sustained KIT/RAS/PI3K signaling carries the transformed germ cell through
    the G1 restriction point into repeated rounds of division without the normal
    requirement for extrinsic growth factors. Clinically this autonomous
    proliferation is what makes MOGCT one of the fastest-growing ovarian
    neoplasms, with symptoms often developing over only weeks.
  cell_types:
  - preferred_term: primordial germ cell
    term:
      id: CL:0000670
      label: primordial germ cell
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      unilateral, large, and grow rapidly
    explanation: >-
      The source describes malignant ovarian germ cell tumors as typically
      unilateral, large, and rapidly growing; rapid autonomous growth is the
      clinical readout of growth-factor-independent proliferation.
  - reference: PMID:33577182
    reference_title: "Dysgerminoma of the Ovary: An Analysis of 140 Cases Emphasizing Unusual Microscopic Findings and Resultant Diagnostic Problems."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The tumors, bilateral in 4% of the cases and with a mean tumor diameter of
      13 cm
    explanation: >-
      Support is partial: the 13 cm mean diameter in a 140-case pure dysgerminoma
      series quantifies the tumor burden produced by autonomous proliferation,
      but the series does not measure proliferation directly.
  downstream:
  - target: Rapidly Expanding Unilateral Ovarian Mass
    description: >-
      Autonomous proliferation produces the characteristic large, fast-growing
      ovarian tumor.

- name: Histology-Determining Epigenetic Reprogramming
  biological_scale: MOLECULAR
  role: driver
  description: >-
    Germ cells undergo complete epigenetic reprogramming during development, and
    the DNA-methylation state at which transformation arrests is a principal
    determinant of which histology results. An epigenome-wide study of 154
    paediatric germ cell tumours identified 8,481 differentially methylated
    regions between histologies, and unsupervised clustering on those regions
    recovered four clusters corresponding to tumour histology rather than to
    age, anatomical location, sex or FFPE status. Germinomatous tumours
    (germinoma/seminoma/dysgerminoma) are globally hypomethylated relative to
    yolk sac tumour. This is the layer that the copy-number arm does not
    explain: 12p gain is shared across MOGCT histologies, so it cannot by itself
    account for the germinomatous versus non-germinomatous split, whereas the
    methylation state clusters by exactly that split.
  notes: >-
    This node closes the epigenetics gap previously disclosed in the entry-level
    notes. The blocker recorded there - that the only cached source was an
    abstract with no quotable methylation sentence - was resolved by caching the
    Children's Oncology Group epigenome-wide study (PMID:30287918) as a citable
    primary source. Scope caveat: that cohort is paediatric germ cell tumours at
    all sites, not ovary-restricted, and the specific IGF2/H19
    imprinting-control claim in the deep-research artifact remains unmodelled
    for want of a snippet-verifiable source.
  cell_types:
  - preferred_term: primordial germ cell
    term:
      id: CL:0000670
      label: primordial germ cell
  biological_processes:
  - preferred_term: epigenetic (DNA methylation) regulation of gene expression
    term:
      id: GO:0040029
      label: epigenetic regulation of gene expression
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:30287918
    reference_title: "Differences in DNA methylation profiles by histologic subtype of paediatric germ cell tumours: a report from the Children's Oncology Group."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified 8,481 DMRs (FWER < 0.05). Unsupervised hierarchical
      clustering of individual probes within DMRs resulted in four high level
      clusters closely corresponding to tumour histology.
    explanation: >-
      Establishes in 154 primary human paediatric germ cell tumours that
      methylation state partitions the tumours by histology, which is the claim
      this node makes.
  - reference: PMID:30287918
    reference_title: "Differences in DNA methylation profiles by histologic subtype of paediatric germ cell tumours: a report from the Children's Oncology Group."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Germinomas displayed lower levels of methylation across the DMRs relative
      to the other histologic subtypes.
    explanation: >-
      Supports the specific germinomatous-hypomethylation direction that
      distinguishes the dysgerminoma arm from the non-germinomatous arm.
  - reference: PMID:30287918
    reference_title: "Differences in DNA methylation profiles by histologic subtype of paediatric germ cell tumours: a report from the Children's Oncology Group."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Abnormal DNA methylation may be important in germ cell tumour (GCT)
      aetiology, as germ cells undergo complete epigenetic reprogramming during
      development.
    explanation: >-
      Gives the developmental rationale linking the primordial germ cell origin
      to epigenetic susceptibility. Marked PARTIAL because the source frames it
      as "may be important" rather than as an established causal claim.
  downstream:
  - target: Divergent Germinomatous and Non-Germinomatous Differentiation
    description: >-
      The methylation state at which the transformed germ cell arrests
      determines whether it follows the germinomatous or the non-germinomatous
      (embryonic/extraembryonic) differentiation programme.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30287918
      reference_title: "Differences in DNA methylation profiles by histologic subtype of paediatric germ cell tumours: a report from the Children's Oncology Group."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Unsupervised hierarchical clustering of individual probes within DMRs
        resulted in four high level clusters closely corresponding to tumour
        histology.
      explanation: >-
        The clustering shows methylation state and histology co-vary tightly.
        Marked INDIRECT because a cross-sectional association cannot establish
        that methylation is upstream of the differentiation choice rather than
        a consequence of it.
- name: Divergent Germinomatous and Non-Germinomatous Differentiation
  biological_scale: CELLULAR
  role: effector
  description: >-
    The histologic diversity of MOGCT reflects which differentiation program the
    transformed pluripotent germ cell adopts. Cells that remain germinoma-like
    produce dysgerminoma (OCT3/4-, NANOG-, SALL4-, CD117-positive, AFP-negative);
    extraembryonic differentiation produces yolk sac tumor (SALL4-, glypican-3-,
    AFP-positive, OCT4-negative) and non-gestational choriocarcinoma;
    embryonic/somatic differentiation produces embryonal carcinoma and immature
    teratoma; simultaneous divergent differentiation produces mixed tumors. The
    resulting immunophenotype is what pathology uses to assign subtype.
  biological_processes:
  - preferred_term: cell differentiation
    modifier: ABNORMAL
    term:
      id: GO:0030154
      label: cell differentiation
  evidence:
  - reference: PMID:22448662
    reference_title: "Diagnostic utility of CD117, CD133, SALL4, OCT4, TCL1 and glypican-3 in malignant germ cell tumors of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All dysgerminomas were positive for OCT4, whereas all YSTs and immature
      teratomas were negative.
    explanation: >-
      Demonstrates that ovarian germ cell tumor subtypes are separated by
      divergent, lineage-specific differentiation programs detectable by
      immunophenotype.
  - reference: PMID:33435376
    reference_title: "Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The primitive GCTs are subdivided into the ovarian counterpart of the male
      testicular seminoma, dysgerminoma (DG), and non-DGs. The development of
      non-DGs is characterized by differentiation into cell histologies that mimic
      embryonic tissues (embryonal carcinoma (EC), teratoma) and extraembryonic
      tissues (yolk sac tumor (YST) or non-gestational choriocarcinoma (CC))
      (Figure 1) [2].
    explanation: >-
      Directly describes the germinomatous versus embryonic/extraembryonic
      differentiation split modeled by this node.
  downstream:
  - target: Lineage-Specific Tumor Marker Secretion
    description: >-
      Each differentiation program secretes a characteristic serum marker.
  - target: Rapidly Expanding Unilateral Ovarian Mass
    description: >-
      All differentiation programs converge on formation of a bulky ovarian
      tumor.
  - target: Peritoneal, Nodal, and Distant Dissemination
    description: >-
      Histology determines the dominant dissemination route (lymphatic for
      dysgerminoma, peritoneal for yolk sac tumor, haematogenous for
      choriocarcinoma).

- name: Lineage-Specific Tumor Marker Secretion
  biological_scale: ORGANISM
  role: consequence
  description: >-
    Because each MOGCT histology recapitulates a different embryonic lineage, each
    secretes a different circulating marker: yolk sac differentiation produces
    alpha-fetoprotein, trophoblastic differentiation produces beta-hCG, and
    dysgerminoma releases lactate dehydrogenase in proportion to tumor burden.
    Embryonal carcinoma can produce either AFP or beta-hCG. This lineage-to-marker
    mapping makes serum markers simultaneously a subtype clue, a staging aid, and
    the principal response and relapse monitor.
  locations:
  - preferred_term: ovary
    term:
      id: UBERON:0000992
      label: ovary
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Serum tumor markers are critical for initial diagnosis and for monitoring
      the disease during and after treatment.
    explanation: >-
      Supports the diagnostic and monitoring role of the lineage-specific serum
      markers modeled by this node.
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Unlike other non-dysgerminomatous germ cell tumors, embryonal carcinoma is
      frequently associated with signs of hormone production, particularly human
      chorionic gonadotropin
    explanation: >-
      Documents histology-specific hormone production, the basis for
      lineage-specific marker secretion.

- name: Rapidly Expanding Unilateral Ovarian Mass
  biological_scale: TISSUE
  role: outcome
  description: >-
    MOGCTs typically form a large, solid or solid-cystic, unilateral ovarian mass
    that enlarges over only weeks. Mass effect and capsular stretch produce
    abdominal pain and distension, and the pedunculated bulky mass is prone to
    torsion or rupture, which can present as an acute abdomen. Rapid growth is
    also why most tumors become symptomatic - and therefore are detected - at an
    early FIGO stage.
  locations:
  - preferred_term: ovary
    term:
      id: UBERON:0000992
      label: ovary
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Common presenting symptoms include abdominal pain and a palpable
      pelvic-abdominal mass. Acute abdominal pain due to tumor torsion or rupture
      is also not uncommon
    explanation: >-
      Directly supports the bulky unilateral mass and its torsion/rupture
      complications as the dominant local manifestation.
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early diagnosis is common due to the rapid tumor growth and symptoms such
      as abdominal pain and distension, leading to favorable prognoses when
      combined with the high chemosensitivity of platinum-based regimens.
    explanation: >-
      Links rapid growth to early symptomatic presentation and favorable
      prognosis.
  downstream:
  - target: Peritoneal, Nodal, and Distant Dissemination
    description: >-
      Capsular rupture and continued growth allow spread beyond the ovary.
  - target: Exquisite Platinum Chemosensitivity
    description: >-
      The resulting tumor, however bulky, remains highly sensitive to
      platinum-based chemotherapy.

- name: Peritoneal, Nodal, and Distant Dissemination
  biological_scale: ORGANISM
  role: consequence
  description: >-
    Spread beyond the ovary follows histology-specific routes: dysgerminoma has
    the highest risk of lymphatic (retroperitoneal nodal) metastasis, yolk sac
    tumor spreads peritoneally as hypervascular implants, and choriocarcinoma
    disseminates haematogenously to lung and liver. Capsular rupture and
    peritoneal spread are the imaging complications specifically sought at
    staging. Because the disease remains chemosensitive, even disseminated
    disease is usually curable, which is why radical cytoreduction is avoided.
  locations:
  - preferred_term: peritoneum
    term:
      id: UBERON:0002358
      label: peritoneum
  - preferred_term: lymph node
    term:
      id: UBERON:0000029
      label: lymph node
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dysgerminomas occasionally involve bilateral ovaries and adjacent
      structures, while yolk sac tumors may spread peritoneally, appearing as
      hypervascular implants on contrast-enhanced
    explanation: >-
      Documents the peritoneal dissemination route and its imaging appearance.
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among germ cell tumors, dysgerminomas have the highest risk of lymphatic
      metastases.
    explanation: >-
      Documents the lymphatic dissemination route that is most pronounced in
      dysgerminoma.
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      choriocarcinomas often metastasize to the lungs and liver
    explanation: >-
      Documents the haematogenous dissemination route of the trophoblastic
      histology.
  downstream:
  - target: Exquisite Platinum Chemosensitivity
    description: >-
      Disseminated germ cell tumor remains chemocurable, which is why
      dissemination does not mandate radical surgery.

- name: Exquisite Platinum Chemosensitivity
  biological_scale: CELLULAR
  role: therapeutic_vulnerability
  description: >-
    Germ cell tumors are among the most chemosensitive solid tumors. Their
    embryonic, pluripotency-associated apoptotic wiring and limited DNA-damage
    tolerance mean cisplatin-induced DNA adducts efficiently trigger apoptosis,
    so bleomycin/etoposide/cisplatin achieves survival above 90% even in advanced
    disease. This is the pathophysiologic reason mutilating surgery is avoided and
    fertility-sparing surgery is oncologically safe. The corollary is that the
    dominant unmet need is the platinum-resistant minority, especially relapsed
    yolk sac tumor, in which nucleotide-excision repair, stemness, and
    detoxification programs restore survival.
  biological_processes:
  - preferred_term: apoptotic process
    modifier: INCREASED
    term:
      id: GO:0006915
      label: apoptotic process
  evidence:
  - reference: PMID:37954076
    reference_title: "Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Both histologies are exquisitely sensitive to platinum chemotherapy, and
      the combination of bleomycin, etoposide, and cisplatin (BEP) yields
      survival rates greater than 90%.
    explanation: >-
      Directly supports the exquisite platinum sensitivity and the resulting
      survival benefit modeled by this node.
  - reference: PMID:37954076
    reference_title: "Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, BEP causes significant, lifelong toxicity (cardiovascular, renal,
      respiratory, and neurological) in these young patients with an expectation
      of cure.
    explanation: >-
      Documents the toxicity burden that motivates de-escalation and surveillance
      strategies in this highly curable disease.
  downstream:
  - target: Platinum-Resistant Relapse
    description: >-
      A minority of tumors escape platinum-induced apoptosis and relapse, which
      is the dominant unmet need in this otherwise curable disease.

- name: Platinum-Resistant Relapse
  biological_scale: ORGANISM
  role: adaptive_escape
  description: >-
    The clinically decisive minority are the tumors that survive platinum. Most
    relapses occur in the first few years and are detected by rising serum
    markers or imaging change; recurrence after primary chemotherapy carries a
    substantially worse prognosis, and relapsed yolk sac tumor in particular is
    the principal unmet need. Management shifts to high-dose chemotherapy with
    stem-cell rescue, selected secondary cytoreduction, or radiotherapy. A
    distinct, non-malignant mimic is growing teratoma syndrome, in which masses
    enlarge during chemotherapy with normalized markers because a benign mature
    teratoma component is proliferating; that entity is chemoresistant by nature
    and is treated by resection alone.
  biological_processes:
  - preferred_term: apoptotic process
    modifier: DECREASED
    term:
      id: GO:0006915
      label: apoptotic process
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients who experience a recurrence of malignant disease after primary
      chemotherapy for malignant ovarian germ cell tumors are associated with a
      poorer prognosis.
    explanation: >-
      Directly supports post-chemotherapy relapse as an adverse-prognosis state
      distinct from the chemosensitive majority.
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Growing teratoma syndrome is characterized by a rapid increase in tumor
      size during chemotherapy, despite normalized tumor markers, due to the
      proliferation of a benign mature teratoma component.
    explanation: >-
      Documents the chemoresistant benign mimic that must be distinguished from
      true platinum-resistant relapse.

phenotypes:
- category: Clinical
  name: Abdominal or Pelvic Pain
  frequency: FREQUENT
  description: >-
    Abdominal or pelvic pain, often developing over only a few weeks because of
    rapid tumor growth, is the most common presenting symptom.
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Common presenting symptoms include abdominal pain and a palpable
      pelvic-abdominal mass.
    explanation: >-
      The source names abdominal pain as a "common" presenting symptom, which
      maps to the FREQUENT band; no quantitative frequency is asserted here
      because the cited abstract gives none.
- category: Clinical
  name: Palpable Pelvic-Abdominal Mass
  frequency: FREQUENT
  description: >-
    A large, usually unilateral, solid or solid-cystic ovarian tumor that is
    palpable on abdominal or pelvic examination and readily seen on ultrasound.
  phenotype_term:
    preferred_term: Abdominal mass
    term:
      id: HP:0031500
      label: Abdominal mass
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Common presenting symptoms include abdominal pain and a palpable
      pelvic-abdominal mass.
    explanation: >-
      The source names a palpable pelvic-abdominal mass as a "common"
      presenting symptom, which maps to the FREQUENT band; no quantitative
      frequency is asserted here because the cited abstract gives none.
- category: Clinical
  name: Ovarian Neoplasm
  description: >-
    The defining structural lesion is a malignant ovarian neoplasm of germ cell
    origin, unilateral in the great majority of cases; bilateral involvement is
    reported in a minority of pure dysgerminomas, with series estimates ranging
    from about 4% to 15%.
  phenotype_term:
    preferred_term: Ovarian neoplasm
    term:
      id: HP:0100615
      label: Ovarian neoplasm
  diagnostic: true
  evidence:
  - reference: PMID:37372675
    reference_title: "Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GCTs represent 2-5% of ovarian cancers, with a yearly incidence of
      4:100,000, and they usually affect young women and adolescents.
    explanation: >-
      Establishes that these are ovarian cancers (ovarian neoplasms) of young
      women and adolescents.
- category: Clinical
  name: Abdominal Distension
  description: >-
    Progressive abdominal distension from tumor bulk, and occasionally from
    ascites, accompanies the enlarging mass.
  phenotype_term:
    preferred_term: Abdominal distention
    term:
      id: HP:0003270
      label: Abdominal distention
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early diagnosis is common due to the rapid tumor growth and symptoms such
      as abdominal pain and distension, leading to favorable prognoses when
      combined with the high chemosensitivity of platinum-based regimens.
    explanation: >-
      Directly names abdominal distension among the presenting symptoms of
      malignant ovarian germ cell tumor.
- category: Clinical
  name: Acute Abdomen From Torsion or Rupture
  frequency: OCCASIONAL
  description: >-
    The bulky, rapidly growing adnexal mass may undergo torsion or rupture,
    producing acute abdominal pain that brings the patient to emergency
    presentation. Germ cell tumors are the histologic group most often found in
    torsioned malignant ovarian masses in children and adolescents.
  phenotype_term:
    preferred_term: Acute abdomen from adnexal torsion or tumor rupture
    term:
      id: HP:0033400
      label: Acute abdomen
    temporality: ACUTE
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Acute abdominal pain due to tumor torsion or rupture is also not uncommon
    explanation: >-
      Directly supports torsion or rupture as a not-uncommon acute presentation,
      consistent with the OCCASIONAL frequency band.
  - reference: PMID:19189702
    reference_title: "Torsion of malignant ovarian tumors in childhood and adolescence."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most common torsioned malignant ovarian tumors were of germ cell
      origin, in both premenarchal and postmenarchal girls.
    explanation: >-
      Supports germ cell tumors as the predominant malignant histology among
      torsioned ovarian masses in this age group.
- category: Laboratory
  name: Elevated Alpha-Fetoprotein
  subtype: Yolk Sac Tumor
  description: >-
    Serum AFP elevation reflects yolk sac differentiation and is characteristic of
    yolk sac tumor and of mixed tumors containing a yolk sac component; embryonal
    carcinoma and immature teratoma may also show elevation.
  phenotype_term:
    preferred_term: Elevated circulating alpha-fetoprotein concentration
    term:
      id: HP:0006254
      label: Elevated circulating alpha-fetoprotein concentration
  reports_on:
  - target: Lineage-Specific Tumor Marker Secretion
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Serum alpha-fetoprotein reflects secretion by yolk-sac-differentiated tumor
      cells.
  evidence:
  - reference: PMID:22448662
    reference_title: "Diagnostic utility of CD117, CD133, SALL4, OCT4, TCL1 and glypican-3 in malignant germ cell tumors of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SALL4 and glypican-3 were strongly positive in 100 and 79.3%,
      respectively, of YSTs.
    explanation: >-
      Support is partial: this series documents the yolk sac tumor lineage
      phenotype by immunohistochemistry rather than measuring serum AFP directly.
  - reference: PMID:27401840
    reference_title: "Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Data on AFP were available to calculate an early AFP decline in 57
      patients.
    explanation: >-
      Confirms that serum AFP is routinely measurable and clinically tracked in
      ovarian yolk sac tumor.
- category: Laboratory
  name: Elevated Beta-Human Chorionic Gonadotropin
  subtype: Non-Gestational Choriocarcinoma
  description: >-
    Beta-hCG elevation reflects trophoblastic differentiation and is
    characteristic of non-gestational choriocarcinoma, frequent in embryonal
    carcinoma, and present in the syncytiotrophoblast-containing minority of
    dysgerminomas.
  phenotype_term:
    preferred_term: Elevated circulating beta chorionic gonadotropin concentration
    term:
      id: HP:6000485
      label: Elevated circulating beta chorionic gonadotropin concentration
  reports_on:
  - target: Lineage-Specific Tumor Marker Secretion
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Serum beta-hCG reflects secretion by trophoblast-differentiated tumor cells.
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Unlike other non-dysgerminomatous germ cell tumors, embryonal carcinoma is
      frequently associated with signs of hormone production, particularly human
      chorionic gonadotropin
    explanation: >-
      Supports beta-hCG production as a histology-linked laboratory feature of
      malignant ovarian germ cell tumors.
  - reference: PMID:40020991
    reference_title: "Nongestational Ovarian Choriocarcinoma with Precocious Puberty in a 7-Year-Old Girl: A Rare Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Laboratory tests revealed elevated estradiol, β-hCG, and CA125 levels, with
      suppressed luteinizing hormone and follicle-stimulating hormone.
    explanation: >-
      Documents marked beta-hCG elevation in a non-gestational ovarian
      choriocarcinoma.
- category: Laboratory
  name: Elevated Lactate Dehydrogenase
  subtype: Dysgerminoma
  description: >-
    LDH is the serum marker most associated with dysgerminoma and generally
    tracks tumor burden; it is less subtype-specific than AFP or beta-hCG and may
    be normal in early-stage disease.
  phenotype_term:
    preferred_term: Increased circulating lactate dehydrogenase concentration
    term:
      id: HP:0025435
      label: Increased circulating lactate dehydrogenase concentration
  reports_on:
  - target: Lineage-Specific Tumor Marker Secretion
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Serum lactate dehydrogenase reflects dysgerminoma tumor burden.
  evidence:
  - reference: PMID:34987988
    reference_title: "Unusual Cases of Pure Malignant Germ Cell Tumors of the Ovary: A Case Series on 10 Years Experience at a Tertiary Care Center."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tumor markers namely AFP, βHCG, and LDH increased in all except the
      patients with immature teratoma.
    explanation: >-
      Supports LDH as part of the routinely elevated serum marker panel in
      malignant ovarian germ cell tumor.
  - reference: PMID:26458677
    reference_title: "Ovarian dysgerminoma with normal serum tumour markers presenting in a child with precocious puberty."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Serum tumour markers including lactate dehydrogenase (LDH), beta-subunit of
      human chorionic gonadotropin (B-hCG) and luteinizing hormone/follicular
      stimulating hormone (LH/FSH) were all normal.
    explanation: >-
      Included as a counter-example: LDH is routinely measured but can be normal
      in early-stage dysgerminoma, so a negative marker panel does not exclude
      disease.
- category: Clinical
  name: Precocious Puberty
  frequency: VERY_RARE
  description: >-
    Hormone-producing components, particularly beta-hCG-secreting trophoblastic
    tissue, can drive isosexual precocious puberty with breast development and
    vaginal bleeding in prepubertal girls; the endocrine picture resolves after
    tumor resection.
  phenotype_term:
    preferred_term: Precocious puberty
    term:
      id: HP:0000826
      label: Precocious puberty
  evidence:
  - reference: PMID:40020991
    reference_title: "Nongestational Ovarian Choriocarcinoma with Precocious Puberty in a 7-Year-Old Girl: A Rare Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A 7-year-old girl presented with early puberty and an abdominal mass.
    explanation: >-
      Documents precocious puberty as a presenting feature of a hormone-producing
      malignant ovarian germ cell tumor.
  - reference: PMID:40020991
    reference_title: "Nongestational Ovarian Choriocarcinoma with Precocious Puberty in a 7-Year-Old Girl: A Rare Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Following tumor resection, her hormone levels normalized, and symptoms
      resolved.
    explanation: >-
      Confirms the tumor-dependent (paraneoplastic-endocrine) nature of the
      precocious puberty.
- category: Clinical
  name: Primary Amenorrhea With Gonadal Dysgenesis
  frequency: VERY_RARE
  description: >-
    In the subset arising on a dysgenetic gonad, primary amenorrhea and absent
    secondary sexual development are the presenting features that should trigger
    karyotyping and evaluation for Y-chromosome material.
  phenotype_term:
    preferred_term: Primary amenorrhea
    term:
      id: HP:0000786
      label: Primary amenorrhea
  evidence:
  - reference: PMID:35935368
    reference_title: "Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and Y chromosomal constitution with different genetic etiologies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      pediatric and adolescent patients with DSD and the presence of the Y
      chromosome who had unambiguous female genitalia and underwent bilateral
      gonadectomy or gonadal biopsy were included in this study
    explanation: >-
      Support is partial: this cohort defines the phenotypically female DSD
      population in which dysgerminoma arises, but the abstract does not itself
      quantify amenorrhea.
- category: Clinical
  name: Gonadal Dysgenesis
  frequency: VERY_RARE
  description: >-
    A dysgenetic streak gonad, most consequentially in 46,XY complete gonadal
    dysgenesis (Swyer syndrome) or Turner syndrome with Y mosaicism, is the
    principal recognized predisposing condition.
  phenotype_term:
    preferred_term: Gonadal dysgenesis
    term:
      id: HP:0000133
      label: Gonadal dysgenesis
  evidence:
  - reference: PMID:35935368
    reference_title: "Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and Y chromosomal constitution with different genetic etiologies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with 46,XY complete gonadal dysgenesis (4/6; 66.7%) had the
      highest tumor occurrence rate.
    explanation: >-
      Directly ties gonadal dysgenesis to the highest observed rate of gonadal
      germ cell neoplasia.
- category: Neurologic
  name: Paraneoplastic Anti-NMDA Receptor Encephalitis
  subtype: Immature Teratoma
  frequency: VERY_RARE
  description: >-
    Ovarian teratomas containing neural tissue that expresses NMDA receptor
    subunits can trigger an antibody-mediated encephalitis with psychiatric
    symptoms, amnesia, seizures, dyskinesias, autonomic instability, and depressed
    consciousness. Tumor resection plus immunotherapy is the definitive treatment,
    which makes this a paraneoplastic syndrome with direct oncologic management
    implications.
  notes: >-
    Scope caveat: the association is with ovarian teratoma broadly, and in the
    defining series the majority of associated tumors were MATURE (benign) cystic
    teratomas, which are explicitly out of scope for this malignant-tumor entry
    and are listed under differential_diagnoses. The phenotype is retained here,
    tagged to the Immature Teratoma subtype, because immature (malignant)
    teratomas also cause it and because finding the tumor changes oncologic
    management; the supporting evidence is therefore marked PARTIAL. Separately,
    HPO has no term for autoimmune or anti-NMDA receptor encephalitis, so this
    phenotype binds the closest available parent (HP:0001298 Encephalopathy) and
    carries the specific syndrome name in preferred_term.
  phenotype_term:
    preferred_term: Anti-NMDA receptor encephalitis
    term:
      id: HP:0001298
      label: Encephalopathy
  evidence:
  - reference: PMID:17262855
    reference_title: "Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eleven patients had teratoma of the ovary (six mature) and one a mature
      teratoma in the mediastinum; five of five tumors examined contained nervous
      tissue that strongly expressed NR2 subunits and reacted with patients'
      antibodies.
    explanation: >-
      Establishes the mechanistic link between ovarian teratoma neural tissue and
      the anti-NMDAR autoantibody response. Support is PARTIAL for this entry
      because the snippet itself records that six of the eleven ovarian tumors
      were mature (benign) teratomas, which fall outside the malignant scope of
      this page.
  - reference: PMID:17262855
    reference_title: "Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Twelve women (14-44 years) developed prominent psychiatric symptoms,
      amnesia, seizures, frequent dyskinesias, autonomic dysfunction, and
      decreased level of consciousness often requiring ventilatory support.
    explanation: >-
      Describes the encephalopathic syndrome captured by this phenotype; the
      preferred_term is deliberately more specific than the bound HPO term.
      PARTIAL for the same scope reason as the preceding item.

histopathology:
- name: Lymphocyte-Rich Fibrous Septa in Dysgerminoma
  description: >-
    Dysgerminoma classically shows nests and sheets of uniform polygonal cells
    with clear cytoplasm separated by fibrous septa containing a conspicuous
    lymphocytic infiltrate - the ovarian mirror image of testicular seminoma.
  finding_term:
    preferred_term: lymphocytic infiltrate in fibrous septa
    term:
      id: NCIT:C35983
      label: Lymphocytic Infiltrate
  subtype: Dysgerminoma
  diagnostic: true
  evidence:
  - reference: PMID:33577182
    reference_title: "Dysgerminoma of the Ovary: An Analysis of 140 Cases Emphasizing Unusual Microscopic Findings and Resultant Diagnostic Problems."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      an alveolar pattern resulting from delicate fibrovascular septa (51%),
      diffuse (33%), macronodular (14%), insular (26%), cords (28%), solid
      tubular (17%), microspaces (sometimes simulating glands) (12%),
      follicle-like spaces (5%), prominent fibrous bands (65%), stromal edema
      (56%), stromal luteinization (9%), granulomatous infiltrate (46%),
      lymphocytic infiltrate (100%)
    explanation: >-
      A 140-case pure ovarian dysgerminoma series quantifying the defining
      morphology: a lymphocytic infiltrate in every case, with fibrovascular
      septa and prominent fibrous bands as the dominant architectural features.
  - reference: PMID:33577182
    reference_title: "Dysgerminoma of the Ovary: An Analysis of 140 Cases Emphasizing Unusual Microscopic Findings and Resultant Diagnostic Problems."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      prominent population of cells with pale to clear cytoplasm (73%)
    explanation: >-
      Quantifies the clear-cytoplasm cell population described in this finding.
- name: Immature Neuroepithelium in Immature Teratoma
  description: >-
    The diagnosis and grading of immature teratoma rest on the amount of primitive
    neuroepithelium, seen as immature tubules and rosettes.
  finding_term:
    preferred_term: neuroepithelial rosette
    term:
      id: HP:0031925
      label: Rosette
  subtype: Immature Teratoma
  diagnostic: true
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of immature teratomas relies on the presence of immature or
      embryonic tissues, with neuroepithelium being the most common immature
      element.
    explanation: >-
      Directly supports immature neuroepithelium as the defining and
      grade-determining histologic element of immature teratoma.
- name: Schiller-Duval Bodies in Yolk Sac Tumor
  description: >-
    Perivascular Schiller-Duval bodies are the classic histologic hallmark of the
    yolk sac tumor component.
  finding_term:
    preferred_term: Schiller-Duval body
    term:
      id: NCIT:C54124
      label: Schiller-Duval Body
  subtype: Yolk Sac Tumor
  diagnostic: true
  evidence:
  - reference: PMID:40818404
    reference_title: "Pediatric vaginal yolk sac tumor: A rare case report and diagnostic challenges."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Histopathologic analysis confirmed YST, supported by characteristic
      Schiller-Duval bodies and markedly elevated alpha-fetoprotein (AFP)
      levels.
    explanation: >-
      Supports Schiller-Duval bodies as the characteristic diagnostic histologic
      feature of yolk sac tumor.
- name: Germ Cell Tumor Immunophenotype
  description: >-
    Immunohistochemistry assigns subtype. Dysgerminoma is OCT3/4-, SALL4-, PLAP-,
    D2-40-, NANOG- and CD117/KIT-positive; yolk sac tumor is SALL4-, glypican-3-
    and AFP-positive but OCT4-negative; embryonal carcinoma adds SOX2 and CD30;
    choriocarcinoma is beta-hCG-positive and OCT3/4-negative.
  finding_term:
    preferred_term: germ cell tumor immunohistochemical marker panel
    term:
      id: NCIT:C40998
      label: Immunophenotypic Finding
  diagnostic: true
  evidence:
  - reference: PMID:22448662
    reference_title: "Diagnostic utility of CD117, CD133, SALL4, OCT4, TCL1 and glypican-3 in malignant germ cell tumors of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All 27 dysgerminomas and all 31 YSTs showed CD117 expression, with only
      nine (29%) positively stained in immature teratomas.
    explanation: >-
      Quantifies CD117/KIT immunoreactivity across ovarian germ cell tumor
      subtypes.
  - reference: PMID:22448662
    reference_title: "Diagnostic utility of CD117, CD133, SALL4, OCT4, TCL1 and glypican-3 in malignant germ cell tumors of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CD117 can be used as a diagnostic marker for dysgerminoma and YST. SALL4 is
      a more sensitive and specific marker for YSTs than glypican-3. SALL4 and
      OCT4 are useful in distinguishing YST from dysgerminoma.
    explanation: >-
      Supports the immunohistochemical panel used to distinguish the malignant
      ovarian germ cell tumor subtypes.

biochemical:
- name: Alpha-Fetoprotein
  biomarker_term:
    preferred_term: Alpha-Fetoprotein
    term:
      id: NCIT:C16278
      label: Alpha-Fetoprotein
  presence: >-
    Elevated in yolk sac tumor and in mixed tumors containing a yolk sac
    component; may also be elevated in embryonal carcinoma and immature teratoma.
  specificity: >-
    Lineage-specific for yolk sac (extraembryonic endodermal) differentiation
    within the germ cell tumor spectrum.
  evidence:
  - reference: PMID:27401840
    reference_title: "Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The serum AFP decline was calculated with the formula previously developed
      and validated in male patients with poor prognosis non-seminomatous germ
      cell tumors.
    explanation: >-
      Supports serum AFP as a quantitative, kinetically interpreted biomarker in
      ovarian yolk sac tumor.
- name: Beta-Human Chorionic Gonadotropin
  biomarker_term:
    preferred_term: Human Chorionic Gonadotropin
    term:
      id: NCIT:C2275
      label: Human Chorionic Gonadotropin
  presence: >-
    Markedly elevated in non-gestational choriocarcinoma, frequently elevated in
    embryonal carcinoma, and elevated in the syncytiotrophoblast-containing
    minority of dysgerminomas.
  specificity: Lineage-specific for trophoblastic differentiation.
  evidence:
  - reference: PMID:40020991
    reference_title: "Nongestational Ovarian Choriocarcinoma with Precocious Puberty in a 7-Year-Old Girl: A Rare Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Laboratory tests revealed elevated estradiol, β-hCG, and CA125 levels, with
      suppressed luteinizing hormone and follicle-stimulating hormone.
    explanation: >-
      Documents beta-hCG as the diagnostic serum biomarker in ovarian
      choriocarcinoma.
- name: Lactate Dehydrogenase
  biomarker_term:
    preferred_term: Lactate Dehydrogenase
    term:
      id: NCIT:C25184
      label: Lactate Dehydrogenase
  presence: >-
    Associated with dysgerminoma and generally proportional to tumor burden; can
    also rise in other MOGCT histologies.
  specificity: >-
    Least subtype-specific of the three standard germ cell tumor markers; may be
    normal in early-stage dysgerminoma.
  notes: >-
    A normal LDH does not exclude dysgerminoma - reported cases present with a
    completely normal marker panel.
  evidence:
  - reference: PMID:34987988
    reference_title: "Unusual Cases of Pure Malignant Germ Cell Tumors of the Ovary: A Case Series on 10 Years Experience at a Tertiary Care Center."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tumor markers namely AFP, βHCG, and LDH increased in all except the
      patients with immature teratoma.
    explanation: >-
      Supports LDH as a measured serum biomarker in malignant ovarian germ cell
      tumor evaluation.
- name: Circulating miR-371a-3p
  biomarker_term:
    preferred_term: MicroRNA 371a-3p
    term:
      id: NCIT:C177289
      label: MicroRNA 371a-3p
  presence: >-
    Emerging circulating biomarker overexpressed across malignant germ cell tumor
    sites and histologies (except pure teratoma); validated mainly in testicular
    germ cell tumor and still investigational in ovarian disease.
  evidence:
  - reference: PMID:38611057
    reference_title: "Advancing GCT Management: A Review of miR-371a-3p and Other miRNAs in Comparison to Traditional Serum Tumor Markers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Circulating levels of germ cell tumor (GCT)-associated miRNAs, such as
      miR-371a-3p, can be utilized as efficient and cost-effective alternatives
      in diagnosing and managing patients presenting with GCTs.
    explanation: >-
      Support is partial because the validation evidence is germ-cell-tumor-broad
      (largely testicular) rather than ovarian-specific.

genetic:
- name: Chromosome 12p Gain / Isochromosome 12p
  presence: >-
    Present in the large majority of malignant ovarian germ cell tumors across
    subtypes, typically absent in pure immature teratoma.
  association: >-
    Keystone somatic cytogenetic lesion of postpubertal-type malignant germ cell
    tumor; supports germ cell tumor classification in diagnostically ambiguous
    cases.
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  evidence:
  - reference: PMID:21523721
    reference_title: "KIT gene mutation and amplification in dysgerminoma of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Chromosome 12p anomalies were found in 82% of the dysgerminomas and did
      not correlate with KIT abnormalities.
    explanation: >-
      Quantifies chromosome 12p abnormality frequency in ovarian dysgerminoma.
  - reference: PMID:2302685
    reference_title: "i(12p) in a malignant ovarian tumor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We have found one or more copies of i(12p) in an ovarian germ cell tumor,
      histologically a yolk sac tumor.
    explanation: >-
      Documents isochromosome 12p in an ovarian germ cell tumor, extending the
      lesion beyond dysgerminoma.
- name: KIT
  gene_term:
    preferred_term: KIT
    term:
      id: hgnc:6342
      label: KIT
  presence: >-
    Activating exon 17 codon 816 mutations and gene amplification each in
    approximately 27% of ovarian dysgerminomas; KIT protein expressed in 87%.
  association: >-
    Somatic oncogenic driver enriched in dysgerminoma; associated with advanced
    stage and proposed as a therapeutic target.
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  subtype: Dysgerminoma
  evidence:
  - reference: PMID:21523721
    reference_title: "KIT gene mutation and amplification in dysgerminoma of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      KIT mutations occur in approximately one-third of cases of dysgerminomas
      and are associated with advanced stage at presentation. KIT is a potential
      therapeutic target for those dysgerminomas that have the mutation.
    explanation: >-
      Directly supports KIT as a recurrent somatic driver in ovarian dysgerminoma
      with stage association and therapeutic relevance.
  - reference: PMID:37954076
    reference_title: "Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They share genetic features including KIT and RAS mutations, amplification
      of chromosome 12p, and expression of pluripotency markers (NANOG (Nanog
      homeobox), OCT3/4 (Octamer-binding transcription factor 3/4), and SAL4
      (Spalt-like trascription factor 4)).
    explanation: >-
      Confirms KIT mutation as a shared genetic feature of dysgerminoma and its
      testicular counterpart seminoma.
- name: KRAS
  gene_term:
    preferred_term: KRAS
    term:
      id: hgnc:6407
      label: KRAS
  presence: Somatic mutation reported particularly in yolk sac tumor.
  association: Somatic oncogenic driver of the RAS-MAPK arm in non-dysgerminomatous MOGCT.
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      KIT mutations are commonly observed in ovarian dysgerminomas and KRAS
      mutations, along with PIK3CA and AKT1 amplifications, are frequently found
      in yolk sac tumors
    explanation: >-
      Supports KRAS mutation as a recurrent somatic alteration in ovarian yolk sac
      tumor.
  - reference: PMID:33435376
    reference_title: "Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A subset of three patients (33.3% of all patients) harbored targetable
      oncogenic mutations in KRAS, KIT, ARID1A.
    explanation: >-
      Molecular profiling series documenting targetable KRAS alterations in
      ovarian yolk sac tumor.
- name: PIK3CA
  gene_term:
    preferred_term: PIK3CA
    term:
      id: hgnc:8975
      label: PIK3CA
  presence: Amplification and mutation reported in yolk sac tumor, including persistent and recurrent disease.
  association: Somatic alteration of the PI3K-AKT arm.
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  evidence:
  - reference: PMID:38733954
    reference_title: "Prognostic factors of 87 ovarian yolk sac tumor (OYST) patients and molecular characteristics of persistent and recurrent OYST."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For the 8 persistent and recurrent OYST: cancer driver genes including
      ANKRD36, ANKRD62, DNAH8, MUC5B, NUP205, RYR2, STARD9, MUC16, TTN, ARID1A
      and PIK3CA were frequently mutated; cell cycle, ABC transporters, HR, NHEJ
      and AMPK signal pathway demonstrated as the most significantly enriched
      pathways; TMB, DNA MMR gene mutation and MSI were significantly higher.
    explanation: >-
      Supports recurrent PIK3CA alteration in persistent and recurrent ovarian
      yolk sac tumor.
- name: Y-Chromosome Material in a Dysgenetic Gonad
  presence: >-
    Constitutional (germline/karyotypic) Y-chromosome material in a phenotypically
    female individual with gonadal dysgenesis - 46,XY complete gonadal dysgenesis
    or 45,X/46,XY and related Turner mosaicism.
  association: >-
    Strongest recognized predisposing constitutional factor for malignant ovarian
    germ cell tumor, acting through gonadoblastoma; underpins the recommendation
    for prophylactic gonadectomy in high-risk syndromes.
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:35935368
    reference_title: "Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and Y chromosomal constitution with different genetic etiologies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Gonadal neoplasia was confirmed in six (27.3%) cases by pathological
      examination of surgical gonadal tissue samples.
    explanation: >-
      Quantifies gonadal neoplasia risk in phenotypically female patients with
      DSD and Y-chromosome material.
  - reference: PMID:39577758
    reference_title: "Gonadal Tumors in Individuals with Turner Syndrome and Y-Chromosome Mosaicism: A Retrospective Multisite Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our data shows a prevalence of 24.6% of gonadal tumors in individuals with
      TS +Y and a relatively low risk of malignant transformation (3.5%).
    explanation: >-
      Provides the contrasting, lower malignant-transformation risk in Turner
      syndrome with Y mosaicism, refining the risk gradient across DSD groups.
  - reference: PMID:39577758
    reference_title: "Gonadal Tumors in Individuals with Turner Syndrome and Y-Chromosome Mosaicism: A Retrospective Multisite Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fourteen (29.8%) had gonadoblastoma. Two (4.3%) had dysgerminoma.
    explanation: >-
      Documents the gonadoblastoma-to-dysgerminoma progression pathway in this
      predisposed population.

diagnosis:
- name: Serum Tumor Marker Panel and Imaging Work-up
  description: >-
    Initial evaluation of a rapidly enlarging adnexal mass in a young patient
    combines serum AFP, beta-hCG, and LDH with pelvic ultrasound and
    cross-sectional imaging (MRI preferred over CT in this young population) for
    characterization and staging.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Serum tumor markers are critical for initial diagnosis and for monitoring
      the disease during and after treatment.
    explanation: >-
      Supports the central diagnostic and monitoring role of the serum marker
      panel.
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Advanced imaging modalities like ultrasound, magnetic resonance imaging,
      and computed tomography are essential for staging, monitoring treatment
      response, and detecting recurrences.
    explanation: >-
      Supports the imaging component of the diagnostic and surveillance work-up.
- name: Histopathology With Immunohistochemistry
  description: >-
    Definitive diagnosis and subtyping require histopathology with an
    immunohistochemical panel (SALL4, OCT3/4, PLAP, CD117/KIT, glypican-3, AFP,
    SOX2, CD30, beta-hCG) to separate the germ cell tumor subtypes from each
    other and from epithelial and sex cord-stromal ovarian neoplasms.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pathology is pivotal for diagnosis, incorporating immunohistochemical
      markers to differentiate malignant ovarian germ cell tumors subtypes,
      including dysgerminomas, yolk sac tumors, and immature teratomas.
    explanation: >-
      Directly supports immunohistochemistry-assisted histopathology as the
      definitive diagnostic modality.
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dysgerminoma is frequently positive for SALL4, OCT3/4, alkaline
      phosphatase, placental-like alkaline phosphatase (PLAP), D2-40, NANOG, and
      SCFR.
    explanation: >-
      Specifies the dysgerminoma immunophenotype used in the diagnostic panel.
- name: Karyotype in Premenarchal Presentation
  description: >-
    Karyotyping is recommended in premenarchal girls presenting with a malignant
    ovarian germ cell tumor to detect an underlying dysgenetic gonad with
    Y-chromosome material, which changes management of the contralateral gonad.
  diagnosis_term:
    preferred_term: karyotyping
    term:
      id: NCIT:C16768
      label: Karyotyping
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A preoperative karyotype is ideally recommended for all premenarchal girls.
    explanation: >-
      Directly supports preoperative karyotyping in premenarchal presentations.

treatments:
- name: Fertility-Sparing Surgery
  description: >-
    Unilateral salpingo-oophorectomy with minimal surgical staging is the standard
    primary treatment for adolescents and young adults, preserving the
    contralateral ovary and uterus. Because germ cell tumors are highly
    chemosensitive, extensive or mutilating cytoreduction is avoided.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: unilateral salpingo-oophorectomy
    term:
      id: NCIT:C94469
      label: Unilateral Salpingo-oophorectomy
  target_mechanisms:
  - target: Rapidly Expanding Unilateral Ovarian Mass
    treatment_effect: INHIBITS
    description: >-
      Resection removes the tumor-bearing ovary while preserving reproductive
      potential.
  evidence:
  - reference: PMID:41001186
    reference_title: "Updates in the Management of Malignant Ovarian Germ Cell Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fertility-sparing surgery, including unilateral salpingo-oophorectomy with
      minimal staging, is recommended for adolescent and young adult patients.
    explanation: >-
      Directly supports fertility-sparing unilateral salpingo-oophorectomy as the
      recommended surgical approach.
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fertility-sparing surgery is the cornerstone of treatment for stage I
      disease, often followed by close surveillance to minimize the long-term
      toxicities of chemotherapy.
    explanation: >-
      Supports fertility-sparing surgery as the cornerstone of stage I management.
- name: BEP Chemotherapy
  description: >-
    Bleomycin, etoposide, and cisplatin is the standard first-line regimen for
    higher-risk stage I and for stage II-IV malignant ovarian germ cell tumors,
    typically for 3-4 cycles. Bleomycin is generally omitted after 3 cycles
    because of cumulative pulmonary toxicity, and it should be avoided in patients
    with pre-existing pulmonary disease and in those over 40 years old.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
    therapeutic_agent:
    - preferred_term: bleomycin
      term:
        id: CHEBI:22907
        label: bleomycin
    - preferred_term: etoposide
      term:
        id: CHEBI:4911
        label: etoposide
    - preferred_term: cisplatin
      term:
        id: CHEBI:27899
        label: cisplatin
  regimen_term:
    preferred_term: BEP regimen
    term:
      id: NCIT:C63488
      label: BEP Regimen
  target_mechanisms:
  - target: Exquisite Platinum Chemosensitivity
    treatment_effect: MODULATES
    description: >-
      Cisplatin-induced DNA adducts exploit the intrinsic apoptotic sensitivity of
      germ cell tumors.
  evidence:
  - reference: PMID:41001186
    reference_title: "Updates in the Management of Malignant Ovarian Germ Cell Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The bleomycin/etoposide/cisplatin regimen remains the first-line therapy.
    explanation: Directly supports BEP as first-line therapy for MOGCT.
  - reference: PMID:37954076
    reference_title: "Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Both histologies are exquisitely sensitive to platinum chemotherapy, and
      the combination of bleomycin, etoposide, and cisplatin (BEP) yields
      survival rates greater than 90%.
    explanation: >-
      Quantifies the survival achieved with BEP in germinomatous germ cell
      tumors.
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Due to the high pulmonary toxicity of bleomycin, it is generally omitted
      after 3 cycles, reaching a maximum total cumulative dose of 270 IU.
    explanation: >-
      Supports the bleomycin cumulative-dose safety constraint described in the
      treatment description.
- name: Risk-Adapted Active Surveillance
  description: >-
    Completely resected, properly staged low-risk disease - stage IA dysgerminoma
    and stage IA grade 1 immature teratoma - is managed by surgery plus
    surveillance rather than adjuvant chemotherapy, because relapse is usually
    salvageable and chemotherapy carries substantial lifelong toxicity in this
    young population. Surveillance combines serial tumor markers with imaging,
    intensified during the first two years.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: active surveillance
  notes: >-
    Left as preferred_term only: no NCIT term reachable from
    "Clinical Intervention or Procedure" (NCIT:C25218) corresponds to
    post-resection active surveillance of a known cancer. "Cancer Screening"
    (NCIT:C15406) is semantically screening of asymptomatic populations and was
    deliberately not used here.
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      According to the ESMO guidelines, Stage IA dysgerminomas and properly
      staged Stage IA Grade 1 immature teratomas should be treated with surgery
      alone, followed by postoperative surveillance.
    explanation: >-
      Directly supports guideline-based surveillance-only management of low-risk
      stage IA disease.
  - reference: PMID:41001186
    reference_title: "Updates in the Management of Malignant Ovarian Germ Cell Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Chemotherapy is not recommended for those with surgically resected immature
      teratomas.
    explanation: >-
      Supports omission of adjuvant chemotherapy after complete resection of
      immature teratoma.
  - reference: clinicaltrials:NCT03067181
    reference_title: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This phase III trial studies how well active surveillance help doctors to
      monitor subjects with low risk germ cell tumors for recurrence after their
      tumor is removed.
    explanation: >-
      Prospective trial evaluating active surveillance in low-risk germ cell
      tumors, including ovarian primaries.
- name: Carboplatin Substitution in Pediatric Patients
  description: >-
    Carboplatin may replace cisplatin in pediatric regimens (for example JEB) to
    reduce nephrotoxicity and ototoxicity while preserving the platinum backbone;
    the cisplatin-versus-carboplatin question in standard-risk disease is under
    randomized evaluation.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
    therapeutic_agent:
    - preferred_term: carboplatin
      term:
        id: CHEBI:31355
        label: carboplatin
    - preferred_term: etoposide
      term:
        id: CHEBI:4911
        label: etoposide
    - preferred_term: bleomycin
      term:
        id: CHEBI:22907
        label: bleomycin
  regimen_term:
    preferred_term: JEB regimen
    term:
      id: NCIT:C67289
      label: JEB Regimen
  target_mechanisms:
  - target: Exquisite Platinum Chemosensitivity
    treatment_effect: MODULATES
    description: >-
      Carboplatin retains platinum-adduct-driven cytotoxicity with a different
      toxicity profile.
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For pediatric patients, carboplatin may be substituted for cisplatin
    explanation: >-
      Directly supports carboplatin substitution in the pediatric setting.
  - reference: clinicaltrials:NCT03067181
    reference_title: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The trial studies whether carboplatin or cisplatin is the preferred
      chemotherapy to use in treating metastatic standard risk germ cell tumors.
    explanation: >-
      Randomized trial directly addressing the carboplatin-versus-cisplatin
      question in standard-risk germ cell tumors.
- name: Paclitaxel-Carboplatin Chemotherapy
  description: >-
    Paclitaxel plus carboplatin is under randomized evaluation as a less toxic
    alternative to BEP in fertility-preserving treatment of MOGCT; retrospective
    data suggest comparable safety and prognosis, but BEP remains standard.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
    therapeutic_agent:
    - preferred_term: paclitaxel
      term:
        id: CHEBI:45863
        label: paclitaxel
    - preferred_term: carboplatin
      term:
        id: CHEBI:31355
        label: carboplatin
  target_mechanisms:
  - target: Exquisite Platinum Chemosensitivity
    treatment_effect: MODULATES
    description: >-
      Preserves platinum-driven cytotoxicity while substituting a taxane for
      bleomycin and etoposide.
  evidence:
  - reference: PMID:36890292
    reference_title: "Fertility and prognosis assessment between bleomycin/etoposide/cisplatin and paclitaxel/carboplatin chemotherapy regimens in the conservative treatment of malignant ovarian germ cell tumors: a multicenter and retrospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The PC regimen is as safe as the BEP regimen for MOGCT patients with
      fertility preservation treatment, and no differences were observed in
      fertility and clinical prognosis.
    explanation: >-
      Retrospective support only; prospective randomized confirmation is still
      pending, hence PARTIAL.
- name: KIT-Directed Targeted Therapy
  description: >-
    KIT inhibition is a mechanistically motivated but so far experimental strategy
    for the roughly one-third of dysgerminomas that carry activating KIT
    mutations; reported clinical success has been limited.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Targeted Therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: imatinib
      term:
        id: CHEBI:45783
        label: imatinib
  target_mechanisms:
  - target: KIT and RAS-PI3K Oncogenic Signaling Activation
    treatment_effect: INHIBITS
    description: >-
      Small-molecule inhibition of the constitutively activated KIT receptor
      tyrosine kinase.
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Emerging targeted therapies and novel approaches, such as KIT inhibitors
      for dysgerminomas with KIT mutations, remain experimental, with limited
      success reported so far.
    explanation: >-
      Support is partial and explicitly qualified: the strategy is biologically
      rational but has not yet demonstrated clinical benefit.
  - reference: PMID:21523721
    reference_title: "KIT gene mutation and amplification in dysgerminoma of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      KIT is a potential therapeutic target for those dysgerminomas that have the
      mutation.
    explanation: >-
      Provides the molecular rationale for KIT-directed therapy in mutated
      dysgerminoma.
- name: Prophylactic Gonadectomy in High-Risk Gonadal Dysgenesis
  description: >-
    Removal of dysgenetic gonads containing Y-chromosome material - most clearly
    indicated in confirmed 46,XY complete gonadal dysgenesis (Swyer syndrome) and
    considered in Turner syndrome with Y mosaicism - is the only established
    primary prevention for malignant ovarian germ cell tumor.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_mechanisms:
  - target: Dysgenetic Gonad With Y-Chromosome Material
    treatment_effect: INHIBITS
    description: >-
      Removes the at-risk tissue before gonadoblastoma progresses to invasive
      dysgerminoma.
  evidence:
  - reference: PMID:35935368
    reference_title: "Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and Y chromosomal constitution with different genetic etiologies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pediatric patients with 46,XY complete gonadal dysgenesis had a
      significantly increased risk of developing gonadal tumors and underwent
      prophylactic gonadectomy as soon as the diagnosis was confirmed
    explanation: >-
      Directly supports prophylactic gonadectomy in the highest-risk dysgenetic
      gonad group.
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      prophylactic gonadectomy may be a reasonable recommendation
    explanation: >-
      Supports prophylactic gonadectomy as a reasonable recommendation in
      high-risk syndromes such as Turner and Swyer syndrome.

- name: High-Dose Chemotherapy With Autologous Stem-Cell Rescue
  description: >-
    For relapse after primary platinum-based chemotherapy, salvage options
    determined by a multidisciplinary team include high-dose chemotherapy with
    stem-cell rescue, further conventional chemotherapy, surgery, radiotherapy,
    or a combination. Evidence in ovarian primaries is largely extrapolated from
    testicular germ cell tumor.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: autologous hematopoietic stem cell transplantation
    term:
      id: NCIT:C16039
      label: Autologous Hematopoietic Stem Cell Transplantation
  target_mechanisms:
  - target: Platinum-Resistant Relapse
    treatment_effect: INHIBITS
    description: >-
      Dose intensification with haematopoietic rescue aims to overcome acquired
      platinum resistance at relapse.
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      High-dose chemotherapy with stem-cell transplantation offers promise in
      select cases, while the role of secondary cytoreductive surgery and
      radiotherapy is limited to specific indications.
    explanation: >-
      Support is partial and explicitly hedged by the source: benefit is
      described as promising in selected cases rather than established.
- name: Secondary Cytoreductive Surgery for Growing Teratoma Syndrome
  description: >-
    Resection is the sole required treatment for growing teratoma syndrome -
    enlarging masses during chemotherapy with normalized tumor markers, driven by
    a proliferating benign mature teratoma component - and may also benefit
    selected recurrent immature teratoma and recurrent mixed malignant germ cell
    tumor. Routine secondary cytoreduction is otherwise of uncertain value in
    this chemosensitive disease.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: cytoreductive surgery
    term:
      id: NCIT:C132068
      label: Cytoreductive Surgery
  target_mechanisms:
  - target: Platinum-Resistant Relapse
    treatment_effect: INHIBITS
    description: >-
      Surgery removes chemoresistant residual tissue that systemic therapy
      cannot eliminate.
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It appears that recurrent immature teratomas, growing teratoma syndrome,
      or recurrent mixed malignant germ cell tumors may benefit from
      cytoreductive surgery
    explanation: >-
      Names the specific recurrence settings in which secondary cytoreduction is
      indicated.
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In these cases, surgery is the sole required treatment, aimed at
      alleviating compression symptoms and disease-related morbidity.
    explanation: >-
      Establishes surgery as the definitive and sufficient treatment of growing
      teratoma syndrome.

differential_diagnoses:
- name: Epithelial Ovarian Carcinoma
  disease_term:
    preferred_term: ovarian carcinoma
    term:
      id: MONDO:0005140
      label: ovarian carcinoma
  description: >-
    The dominant ovarian malignancy overall, but typically in older patients,
    CA-125-driven rather than AFP/beta-hCG-driven, and biologically and
    therapeutically distinct from germ cell tumors.
  distinguishing_features:
  - Older age at onset
  - Epithelial immunophenotype (PAX8, CK7) without germ cell markers (SALL4, OCT3/4, CD117)
  - Absence of chromosome 12p gain
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Non-epithelial ovarian tumors constitute approximately 10% of all ovarian
      cancers, with malignant ovarian germ cell tumors accounting for about 5%
    explanation: >-
      Frames germ cell tumors as a small non-epithelial minority that must be
      distinguished from the far more common epithelial ovarian cancers.
- name: Mature Cystic Teratoma
  disease_term:
    preferred_term: mature ovarian teratoma
    term:
      id: MONDO:0003820
      label: mature ovarian teratoma
  description: >-
    The benign counterpart of immature teratoma (dermoid cyst); far more common
    and managed by cystectomy alone.
  distinguishing_features:
  - Absence of immature (usually neuroepithelial) tissue on thorough sampling
  - Normal serum tumor markers
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of immature teratomas relies on the presence of immature or
      embryonic tissues, with neuroepithelium being the most common immature
      element.
    explanation: >-
      Identifies the histologic criterion that separates immature (malignant)
      from mature (benign) teratoma.

- name: Small Cell Carcinoma of the Ovary, Hypercalcemic Type
  disease_term:
    preferred_term: hypercalcemic type ovarian small cell carcinoma
    term:
      id: MONDO:0004319
      label: hypercalcemic type ovarian small cell carcinoma
  description: >-
    A highly aggressive SMARCA4-deficient ovarian malignancy that also affects
    young women and can mimic dysgerminoma microscopically.
  distinguishing_features:
  - Hypercalcemia and SMARCA4/BRG1 loss by immunohistochemistry
  - Absence of germ cell markers (SALL4, OCT3/4, CD117) and of a lymphocytic infiltrate
  - Markedly worse prognosis and platinum-refractory behaviour
  evidence:
  - reference: PMID:33577182
    reference_title: "Dysgerminoma of the Ovary: An Analysis of 140 Cases Emphasizing Unusual Microscopic Findings and Resultant Diagnostic Problems."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      certain tumors of very different nature being in the differential such as
      undifferentiated carcinoma not otherwise specified, small cell carcinoma of
      hypercalcemic type, and malignant lymphoma
    explanation: >-
      A 140-case dysgerminoma series naming small cell carcinoma of hypercalcemic
      type among the tumors that variant dysgerminoma morphology can mimic.
- name: Malignant Lymphoma Involving the Ovary
  disease_term:
    preferred_term: ovarian lymphoma
    term:
      id: MONDO:0002227
      label: ovarian lymphoma
  description: >-
    Ovarian involvement by lymphoma produces a diffuse population of
    discohesive cells that can be mistaken for dysgerminoma.
  distinguishing_features:
  - CD45/lymphoid immunophenotype with absent SALL4, OCT3/4 and CD117
  - Absence of fibrovascular septa and of chromosome 12p gain
  evidence:
  - reference: PMID:33577182
    reference_title: "Dysgerminoma of the Ovary: An Analysis of 140 Cases Emphasizing Unusual Microscopic Findings and Resultant Diagnostic Problems."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      certain tumors of very different nature being in the differential such as
      undifferentiated carcinoma not otherwise specified, small cell carcinoma of
      hypercalcemic type, and malignant lymphoma
    explanation: >-
      The same dysgerminoma series names malignant lymphoma as a recognized
      diagnostic pitfall.

clinical_trials:
- name: NCT03067181
  phase: PHASE_III
  status: RECRUITING
  description: >-
    Pediatric and adult germ cell tumor trial (AGCT1531) combining active
    surveillance for low-risk disease with a randomized comparison of
    carboplatin- versus cisplatin-based chemotherapy for standard-risk metastatic
    disease. Directly relevant to both the de-escalation and the
    platinum-selection questions in malignant ovarian germ cell tumor.
  target_phenotypes:
  - preferred_term: Ovarian neoplasm
    term:
      id: HP:0100615
      label: Ovarian neoplasm
  evidence:
  - reference: clinicaltrials:NCT03067181
    reference_title: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The trial studies whether carboplatin or cisplatin is the preferred
      chemotherapy to use in treating metastatic standard risk germ cell tumors.
    explanation: >-
      Trial directly addresses platinum selection and treatment de-escalation
      across pediatric and adult germ cell tumors including ovarian primaries.
- name: NCT02429687
  phase: PHASE_III
  status: RECRUITING
  description: >-
    MOGCT-01, an ovarian-specific randomized phase III trial comparing
    paclitaxel/carboplatin with BEP after surgery in newly diagnosed malignant
    ovarian germ cell tumor.
  target_phenotypes:
  - preferred_term: Ovarian neoplasm
    term:
      id: HP:0100615
      label: Ovarian neoplasm
  notes: >-
    The falcon deep-research report flagged that the registry eligibility field
    for this study inconsistently mentions sex cord-stromal histologies despite
    the title and intervention summary specifying MOGCT; eligibility should be
    verified directly before referral.
  evidence:
  - reference: clinicaltrials:NCT02429687
    reference_title: "A Multicenter, Prospective, Randomized Trial Comparing Paclitaxel and Carboplatin or Bleomycin, Etoposide and Cisplatin in the Treatment of Malignant Ovarian Germ Cell Tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Investigators will conduct the trial to determine whether paclitaxel and
      cisplatin (PT) has the same curative effects and less adverse effects than
      bleomycin, etoposide and cisplatin(BEP) among newly diagnosed malignant
      ovarian germ cell tumor patients after surgery.
    explanation: >-
      Ovarian-specific randomized evaluation of a less toxic alternative to BEP.

references:
- reference: PMID:37296950
  title: "Molecular Biology of Pediatric and Adult Ovarian Germ Cell Tumors: A Review"
  found_in:
  - Malignant_Germ_Cell_Tumor_of_Ovary-deep-research-falcon.md
  findings:
  - statement: >-
      Ovarian germ cell tumors are rare and occur predominantly in children,
      adolescents, and young adults, accounting for roughly 11% of cancer
      diagnoses in those age groups.
    supporting_text: >-
      Ovarian germ cell tumors (OGCTs) are rare in adults; indeed, they occur
      predominantly in children, adolescents, and young adults, and they account
      for approximately 11% of cancer diagnoses in these groups.
- reference: PMID:37372675
  title: Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours
  found_in:
  - Malignant_Germ_Cell_Tumor_of_Ovary-deep-research-falcon.md
  findings:
  - statement: >-
      Epidemiology, histologic classification, marker use, and management
      challenges for malignant ovarian germ cell tumors.
    supporting_text: >-
      GCTs represent 2-5% of ovarian cancers, with a yearly incidence of
      4:100,000, and they usually affect young women and adolescents.
- reference: PMID:35935368
  title: >-
    Gonadal tumor risk in pediatric and adolescent phenotypic females with
    disorders of sex development and Y chromosomal constitution with different
    genetic etiologies
  found_in:
  - Malignant_Germ_Cell_Tumor_of_Ovary-deep-research-falcon.md
  findings:
  - statement: >-
      Dysgenetic gonads with Y-chromosome material carry the highest recognized
      germ cell tumor risk, greatest in 46,XY complete gonadal dysgenesis.
    supporting_text: >-
      Gonadal neoplasia was confirmed in six (27.3%) cases by pathological
      examination of surgical gonadal tissue samples.

notes: >-
  Scope and lump/split boundary. This entry is the umbrella (root) MOGCT page for
  MONDO:0018171 and is deliberately complementary to three pre-existing dismech
  entries rather than a superset of them:
  Malignant_Non_Dysgerminomatous_Germ_Cell_Tumor_Of_Ovary (MONDO:0016096, the
  non-dysgerminomatous half of the same split), Yolk_Sac_Tumor (MONDO:0005744,
  site-agnostic), and Mixed_Germ_Cell_Tumor (MONDO:0015864, site-agnostic). To
  avoid duplication, mechanism here is curated (a) on the axis shared by all
  MOGCT histologies - primordial germ cell origin with retained pluripotency,
  chromosome 12p gain, lineage-specific marker secretion, bulky unilateral mass,
  platinum chemosensitivity - and (b) on the dysgerminoma arm and the dysgenetic
  gonad/Y-chromosome predisposition, neither of which is covered by any existing
  dismech entry (there is no standalone Dysgerminoma page). Yolk sac tumor,
  immature teratoma, embryonal carcinoma, choriocarcinoma, and mixed tumors are
  represented as has_subtypes with cross-references, and their subtype-specific
  detail is intentionally left in the dedicated entries. Mechanisms from
  epithelial ovarian carcinoma pages must not be imported here.

  Open modelling question for reviewers: MONDO also carries
  MONDO:0020538 "malignant dysgerminomatous germ cell tumor of ovary" as the
  exact sibling of MONDO:0016096. A cleaner long-term structure would be a
  dedicated Malignant_Dysgerminomatous_Germ_Cell_Tumor_Of_Ovary Disease entry
  mirroring the existing non-dysgerminomatous one, with MONDO:0018171 modeled as
  a kb/groupings/ Grouping over the two. That restructuring is deliberately NOT
  attempted here because it would also require rewriting an existing entry;
  flagging it instead for a curator decision.

  Known content gap: the epigenetic arm of MOGCT biology - global hypomethylation
  in dysgerminoma versus relative hypermethylation in yolk sac tumor, IGF2/H19
  imprinting-control hypomethylation, and the miR-371-373 / miR-302-367 clusters -
  is described in the deep-research source (PMID:37296950). This gap is now
  PARTIALLY CLOSED: the Children's Oncology Group epigenome-wide study
  (PMID:30287918, 154 paediatric germ cell tumours) has been cached as a citable
  primary source and is modeled as the "Histology-Determining Epigenetic
  Reprogramming" pathophysiology node, covering the 8,481-DMR
  histology-partitioning result and the germinoma-hypomethylation direction.
  Still unmodeled for want of a snippet-verifiable source: the IGF2/H19
  imprinting-control-region hypomethylation claim and the miR-371-373 /
  miR-302-367 cluster biology (the latter is represented on the biomarker side
  as circulating miR-371a-3p but not as a mechanism node). Note also that the
  COG cohort is paediatric germ cell tumours at all sites rather than
  ovary-restricted; that scope caveat is recorded on the node itself.

  Prevalence scope. A previously curated third prevalence record - "ovarian germ
  cell tumors account for approximately 11% of cancer diagnoses in children,
  adolescents, and young adults" (PMID:37296950) - has been removed from
  `prevalence`. That figure is a case-mix proportion of cancer diagnoses, not a
  population occurrence measure, so it could not be given an honest
  `measure_type` or `prevalence_class`; it is recorded here instead. The age
  skew it describes is still modeled, in `progression`.

📚

References & Deep Research

References

3

PMID:37296950

Molecular Biology of Pediatric and Adult Ovarian Germ Cell Tumors: A Review

1 finding

Ovarian germ cell tumors are rare and occur predominantly in children, adolescents, and young adults, accounting for roughly 11% of cancer diagnoses in those age groups.

"Ovarian germ cell tumors (OGCTs) are rare in adults; indeed, they occur predominantly in children, adolescents, and young adults, and they account for approximately 11% of cancer diagnoses in these groups."

PMID:37372675

Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours

1 finding

Epidemiology, histologic classification, marker use, and management challenges for malignant ovarian germ cell tumors.

"GCTs represent 2-5% of ovarian cancers, with a yearly incidence of 4:100,000, and they usually affect young women and adolescents."

PMID:35935368

Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and Y chromosomal constitution with different genetic etiologies

1 finding

Dysgenetic gonads with Y-chromosome material carry the highest recognized germ cell tumor risk, greatest in 46,XY complete gonadal dysgenesis.

"Gonadal neoplasia was confirmed in six (27.3%) cases by pathological examination of surgical gonadal tissue samples."

Deep Research

1

Falcon ▸

Malignant Germ Cell Tumor of the Ovary: Disease-Characteristics Report

Edison Scientific Literature 38 citations 2026-07-31T23:41:55.749609

Malignant Germ Cell Tumor of the Ovary: Disease-Characteristics Report

Executive summary

Malignant ovarian germ-cell tumors (MOGCTs) are a heterogeneous group of rare, rapidly growing neoplasms derived from primordial germ-cell lineages. They predominantly affect children, adolescents, and young adults, most often presenting with acute or subacute abdominal pain and a rapidly enlarging adnexal mass. Major histologies are dysgerminoma, yolk-sac tumor (YST), immature teratoma, mixed germ-cell tumor, embryonal carcinoma, and nongestational choriocarcinoma. Unlike epithelial ovarian cancers, MOGCTs usually have a low point-mutation burden but marked chromosomal, imprinting, and DNA-methylation abnormalities. Fertility-sparing surgery and platinum-based chemotherapy cure most newly diagnosed patients; recurrent, platinum-resistant YST is the principal unmet clinical need. (pinto2023molecularbiologyof pages 4-6, saani2023clinicalchallengesin pages 2-3, pinto2023molecularbiologyof pages 1-3, pinto2023molecularbiologyof pages 16-18)

The following matrix summarizes the most transferable evidence.

Domain	Key quantitative findings	Practical interpretation	Evidence type and date
Disease definition / epidemiology	Malignant ovarian germ cell tumors (MOGCTs) are rare, comprising 2–5% of ovarian cancers; annual incidence reported as 4:100,000 and approximately 4 per 1,000,000 women; most occur at ages 10–25 years with median diagnosis age 18; 60–70% present as early-stage disease; common symptoms are abdominal pain (87%) and palpable mass (85%) (saani2023clinicalchallengesin pages 1-2, saani2023clinicalchallengesin pages 2-3, saani2023clinicalchallengesin pages 5-6)	Rare, usually adolescent/young-adult ovarian cancers that often present early but require rapid evaluation because symptoms are nonspecific	Human clinical review, 2023; review with compiled epidemiology, 2023
Major subtypes	Dysgerminoma accounts for 35–50% globally; dysgerminoma and immature teratoma together comprise 65–70% of cases; yolk sac tumor (YST) 14.5%; mixed germ cell tumors 5.3%; embryonal carcinoma ~4%; bilateral disease occurs in 10–15% of pure dysgerminomas and 5–10% of mixed tumors (saani2023clinicalchallengesin pages 2-3, pinto2023molecularbiologyof pages 4-6)	Histology strongly determines marker use, surgical decisions, and adjuvant chemotherapy needs	Human clinical and molecular reviews, 2023
Biomarkers	AFP is elevated in YST and can be elevated in embryonal carcinoma/immature teratoma; β-hCG is associated with choriocarcinoma and some embryonal carcinomas; LDH is used in dysgerminoma; in a 2024 pelvic YST series, AFP rose in all 16/16 and CA125 increased in 58.33% (7/12); YST ultrasound series showed 81.25% ovarian location (13/16) with rich vascularity in solid/cystic-solid lesions (saani2023clinicalchallengesin pages 2-3, saani2023clinicalchallengesin pages 3-5)	AFP/β-hCG/LDH remain the core clinical markers; imaging plus markers helps distinguish subtype and guide fertility-preserving planning	Human clinical review, 2023; single-center retrospective imaging/pathology study, 2024
Genomics / epigenetics	Overall mutation burden is low; chromosome 12p gain is a keystone feature, observed in 44% (15/34) of malignant GCTs in one series and in 10/14 tumors in patients <15 years in another summary; KIT was the most significantly mutated gene with 4/24 cases (16.7%) in a genetic landscape study; PIK3CA amplification occurred in 21.8% (19/87) and AKT amplification in 20.6% (18/87); pediatric cohort copy-number gains included 20q (57%) and 12p (39%), with 40% of the 12p-gain group carrying i(12p); dysgerminomas/germinomas are globally hypomethylated, while more differentiated tumors such as YST are relatively hypermethylated; 8,481 differentially methylated regions were identified in one pediatric cohort; miR-371~373 and miR-302 clusters are recurrently overexpressed across malignant GCTs (pinto2023molecularbiologyof pages 9-11, pinto2023molecularbiologyof pages 11-12, pinto2023molecularbiologyof pages 12-13)	Biology is driven more by copy-number/epigenetic dysregulation than high mutational burden; KIT/RAS/PI3K and methylation states are the main molecular leads for stratification and research	Human molecular review synthesizing genomic/epigenetic studies, 2023
Standard treatment	Stage IA dysgerminoma and grade 1 stage IA immature teratoma: unilateral salpingo-oophorectomy (USO) with surveillance; higher-risk stage I disease often receives 3–4 cycles BEP; stages II–IV generally receive surgery plus 3–4 cycles BEP, with EP considered in older patients; stage IA pure dysgerminoma has a surgery-only recurrence rate of 15–25%; BEP doses summarized as bleomycin 30 IU, cisplatin 20 mg/m² days 1–5, etoposide 100 mg/m² days 1–5 every 3 weeks for 3–4 cycles; ongoing phase III MOGCT-01 randomizes paclitaxel/carboplatin vs BEP, planned enrollment 129 (saani2023clinicalchallengesin pages 5-6, pinto2023molecularbiologyof pages 6-7, saani2023clinicalchallengesin pages 6-8, NCT02429687 chunk 1)	Fertility-sparing surgery is standard whenever feasible; BEP remains the backbone, but de-escalation/substitution strategies are under active testing to reduce toxicity	Human clinical reviews, 2023; ClinicalTrials.gov registry updated 2023
Prognosis / fertility	Early-stage survival reported as 82–100% and late-stage survival as 75%; stage I disease has about 90% long-term disease-free survival; in one long follow-up fertility-preservation cohort, 42/45 women achieved pregnancy, with 65 pregnancies and 56 births among 40 survivors; another cohort had 31/39 patients with 33 uneventful pregnancies; 75.6% maintained regular menstruation after treatment; published pregnancy rates range 18.8–55.7% (saani2023clinicalchallengesin pages 3-5, saani2023clinicalchallengesin pages 5-6)	Cure rates are high and post-treatment fertility is often preserved, supporting conservative surgery and survivorship counseling	Human clinical review summarizing cohort studies, 2023
Relapse / current research	Recurrences commonly occur within 2 years and often involve peritoneal/retroperitoneal lymph nodes; more than 50% of relapsed YST patients die of disease; salvage regimens include TIP, VeIP, and TI-CE with stem-cell support; targeted agents such as everolimus, imatinib, sunitinib, and pazopanib showed reported response rates of 0–13%; brentuximab vedotin produced responses in 2/9 patients (22%); accelerated BEP is under phase III evaluation in GCTs (NCT02582697) and ovarian-specific MOGCT-01 compares paclitaxel/carboplatin with BEP (saani2023clinicalchallengesin pages 6-8, saani2023clinicalchallengesin pages 8-9, pinto2023molecularbiologyof pages 16-18, NCT02429687 chunk 1)	Relapse remains the main unmet need; current research focuses on optimizing salvage chemotherapy and testing lower-toxicity or targeted/immunologic approaches, but evidence is still limited	Human clinical and molecular reviews, 2023; clinical trial registry updated 2023
Models	Ovarian-specific models remain scarce; NOY1/NOY2 were the first ovarian YST cell lines; cisplatin-resistant NOY1-CR became 22.3-fold more cisplatin-resistant than parent cells; GSTA1 overexpression was linked to resistance and its inhibition restored cisplatin sensitivity; TC587 is a YST line expressing AFP and SALL4 with NRAS, KIT, KMT2C, RSF1, and TP53 mutations; NOY1-CR formed larger mouse xenografts and showed CAM micrometastasis; a pediatric ovarian YST PDX treated with bleomycin/etoposide/cisplatin mirrored clinical response; the review states no established dedicated ovarian GCT PDX platform was yet available broadly (pinto2023molecularbiologyof pages 13-15, pinto2023molecularbiologyof pages 15-16)	Preclinical work is possible but limited by model scarcity; current models are strongest for studying cisplatin resistance and candidate targeted therapies in YST	In vitro/in vivo model review, 2023

Table: Compact evidence matrix summarizing the highest-yield disease, molecular, diagnostic, treatment, prognosis, relapse, and model findings for malignant ovarian germ cell tumors. It is useful for quickly transferring supported facts into a disease knowledge-base entry.

1. Disease information

Definition and classification

MOGCT is an umbrella disease category rather than one molecularly uniform cancer. It comprises malignant neoplasms showing germinoma-like, extraembryonic, embryonal, or somatic differentiation:

Dysgerminoma—ovarian counterpart of testicular seminoma.
Yolk-sac tumor/endodermal sinus tumor.
Immature teratoma, graded by the amount of immature neuroepithelium.
Mixed germ-cell tumor containing two or more malignant components.
Embryonal carcinoma and nongestational choriocarcinoma, both very rare.
Gonadoblastoma is a precursor/mixed lesion arising especially in dysgenetic gonads and can be overgrown by dysgerminoma.

Dysgerminoma and immature teratoma together account for approximately 65–70% of cases; YST accounts for about 14.5%, mixed tumors 5.3%, and embryonal carcinoma approximately 4%. Dysgerminoma alone represents roughly 35–50% of MOGCTs. (pinto2023molecularbiologyof pages 4-6, saani2023clinicalchallengesin pages 3-5, saani2023clinicalchallengesin pages 2-3)

A useful verbatim summary from the 2023 molecular review is: “OGCTs are rare tumors … [and] occur predominantly in children, adolescents, and young adults.” The same review stresses that few ovarian-specific molecular studies exist. (pinto2023molecularbiologyof pages 1-3)

Identifiers and synonyms

Preferred label: malignant ovarian germ cell tumor; malignant germ cell tumor of ovary.
Synonyms: ovarian germ-cell cancer, malignant ovarian germ-cell neoplasm, MOGCT, malignant OGCT.
MeSH: Ovarian Germ Cell Cancer, MeSH supplementary concept C562841; broader term Ovarian Neoplasms, D010051. (NCT02429687 chunk 1, NCT02429687 chunk 2)
ICD-10-CM: generally coded by site as C56.-, malignant neoplasm of ovary; morphology requires an oncology morphology system such as ICD-O-3.
ICD-O-3: histology-specific morphology codes should be used—for example, dysgerminoma, yolk-sac tumor, immature teratoma, or mixed germ-cell tumor—together with ovarian topography C56.9.
MONDO/Orphanet/OMIM: a single umbrella identifier was not verified in the retrieved primary literature. The individual histologies may have separate ontology entries. Curators should resolve the current MONDO and Orphanet release rather than assign an unverified identifier. OMIM is not the primary classification system for this mostly somatic cancer.

The report synthesizes aggregated disease-level literature and trial records, not individual EHR data. Some cited cohorts were retrospective patient-level studies, but no identifiable patient record was accessed.

2. Etiology, risk, and protective factors

Causal framework

Most cases are sporadic. The best-supported model is aberrant transformation of a primordial germ cell or oocyte-lineage cell during germ-cell specification, migration, gonadal colonization, meiosis, or epigenetic reprogramming. Pluripotency programs involving POU5F1/OCT3/4, NANOG, SOX2/SOX17, PRDM1, and PRDM14 remain active; subsequent copy-number changes, KIT–RAS signaling, lineage-specific methylation, and differentiation state determine histology. Immature teratomas appear particularly related to meiotic error and parthenogenetic/oocyte-like development rather than recurrent somatic driver mutations. (pinto2023molecularbiologyof pages 4-6, saani2023clinicalchallengesin pages 8-9)

Established genetic/developmental risk

The strongest recognized predisposition is a disorder/difference of sex development with a dysgenetic gonad and Y-chromosome material, especially the gonadoblastoma region of Y. In a 22-patient pediatric series, 6/22 (27.3%) had gonadal neoplasia. Rates were 4/6 (66.7%) in 46,XY complete gonadal dysgenesis, 1/10 (10%) in Turner syndrome with Y material, and 1/6 (16.6%) in androgen synthesis/action disorders. All tumors arose in streak-gonad tissue; gonadoblastoma and dysgerminoma predominated. Estimates are imprecise because cohorts are small and management practices differ. (lu2022gonadaltumorrisk pages 6-7, lu2022gonadaltumorrisk pages 1-2, lu2022gonadaltumorrisk pages 5-6)

Risk is enhanced by an intra-abdominal gonad, incomplete germ-cell maturation, expression of OCT3/4 and TSPY, and increasing age. A 2023 Swyer-syndrome report emphasized that primary amenorrhea and absent secondary sexual development should trigger DSD assessment even when imaging and serum markers are unrevealing. (sowinskaprzepiera2023latediagnosisof pages 1-2, piazza2019germcelltumors pages 1-2)

Environmental, lifestyle, infectious, and protective factors

No reproducible causal association with smoking, alcohol, diet, obesity, occupational toxins, pollution, radiation, or an infectious agent was established in the retrieved ovarian-specific literature. No validated protective germline allele, dietary intervention, medication, or vaccine is known. Complete androgen insensitivity may confer lower childhood malignant transformation risk than complete gonadal dysgenesis, but it should not be treated as a general protective factor; risk rises with age and remains management-dependent. (piazza2019germcelltumors pages 4-5, lanciotti2019differentclinicalpresentations pages 3-5)

Accordingly, no clinically validated gene–environment interaction has been established. Apparent references to carcinogen-related methylation are generic cancer biology and not evidence that a specific exposure causes MOGCT. (pinto2023molecularbiologyof pages 11-12)

3. Phenotypes

The typical onset is pediatric, adolescent, or young-adult. Most cases occur at 10–25 years, with a reported median age of 18. Symptoms often develop over only 2–4 weeks, reflecting rapid tumor growth. Abdominal pain occurs in approximately 87% and a palpable abdominal/pelvic mass in 85%. Possible manifestations include abdominal distension, nausea/vomiting, torsion or rupture, menstrual disturbance, precocious puberty or virilization from hormone-producing components, ascites, and symptoms from metastatic peritoneal, nodal, hepatic, or pulmonary disease. (saani2023clinicalchallengesin pages 2-3, saani2023clinicalchallengesin pages 1-2)

Suggested HPO annotations are Abdominal pain (HP:0002027), abdominal distention, pelvic mass, ovarian neoplasm, nausea and vomiting, ascites, menstrual irregularity, primary amenorrhea, elevated serum AFP, elevated serum β-hCG, and elevated serum LDH. Frequencies beyond pain and palpable mass are not robustly quantified.

Laboratory phenotype depends on histology:

YST: AFP elevation is characteristic.
Choriocarcinoma: β-hCG elevation.
Embryonal carcinoma: AFP and/or β-hCG.
Dysgerminoma: LDH may be elevated; a minority containing syncytiotrophoblast can produce β-hCG.
Immature teratoma: AFP should prompt evaluation for a YST component, although modest elevations can occur.

A 2024 series of 16 female pelvic YSTs found AFP elevation in every patient and CA-125 elevation in 7/12 (58.33%). Thirteen of 16 lesions (81.25%) were ovarian. These data are useful but derive from a small referral cohort.

Quality-of-life burdens include acute pain, hospitalization, chemotherapy toxicity, fear of recurrence, altered body image and sexuality, premature ovarian insufficiency, and uncertainty about fertility. Fertility-sparing treatment improves reproductive opportunity, but formal EQ-5D, SF-36, or PROMIS estimates were not available in the retrieved ovarian-specific evidence. (saani2023clinicalchallengesin pages 5-6)

4. Genetic and molecular information

Somatic alterations

MOGCT is not usually a single-gene Mendelian disorder. Its defining molecular pattern is low somatic point-mutation burden with aneuploidy, copy-number imbalance, and epigenetic reprogramming. Recurrent alterations include:

12p gain or i(12p): a keystone feature of postpubertal malignant GCT. One series found 12p gain in 15/34 (44%) malignant tumors. In a pediatric multi-omic cohort, 12p gain occurred in 39%, and 40% of that group carried i(12p).
Other recurrent gains include 20q, 21, 8, and 1q; chromosome 13 loss occurs in some tumors.
KIT activating mutations, commonly exon 17, are enriched in dysgerminoma. In one 87-tumor landscape study, nonsynonymous KIT variants occurred in 4/24 sequenced cases (16.7%).
KRAS/NRAS mutations occur less frequently; recurrent KRAS codon-12 variants have been reported.
PIK3CA amplification occurred in 19/87 (21.8%) and AKT amplification in 18/87 (20.6%).
YST studies report KRAS, KIT, occasional TP53, deletion of ARID1A/PARK2, and amplification of ZNF217, CDKN1B, and KRAS.
Immature teratomas often have near-diploid genomes with extensive loss of heterozygosity but few or no recurrent somatic driver mutations. (pinto2023molecularbiologyof pages 7-9, pinto2023molecularbiologyof pages 9-11)

These are predominantly somatic alterations. Population allele frequencies are therefore not meaningful in the way they are for inherited disorders. Their presence does not currently mandate routine germline testing. Germline karyotyping or DSD-focused testing is appropriate when there is primary amenorrhea, absent puberty, virilization, bilateral dysgenetic gonads, Turner mosaicism, or other syndromic findings.

Epigenetics, transcriptomics, and noncoding RNA

Dysgerminoma/germinoma is globally hypomethylated and retains pluripotency expression. More differentiated YST, teratoma, and choriocarcinoma are relatively hypermethylated; embryonal carcinoma is intermediate. In 154 pediatric GCTs, 8,481 differentially methylated regions were identified, with dysgerminoma/germinoma showing reduced methylation in angiogenesis and immune pathways and YST showing tumor-suppressor hypermethylation. All eight ovarian GCTs in one IGF2/H19 study were hypomethylated at that imprinting-control region. (pinto2023molecularbiologyof pages 11-12)

YSTs overexpress endodermal programs such as GATA6 and FOXA2 and show WNT/β-catenin and TGF-β/BMP pathway enrichment. The miR-371–373 and miR-302–367 clusters are overexpressed across malignant GCT sites and histologies. Their clinical use in ovarian disease remains investigational; the strongest validation currently comes from testicular GCT, where miR-371a-3p reached 84.7% sensitivity and 99% specificity in one cited study. (pinto2023molecularbiologyof pages 9-11, pinto2023molecularbiologyof pages 12-13)

Suggested annotations

GO biological processes: primordial germ-cell development; germ-cell migration; DNA methylation/demethylation; genomic imprinting; regulation of cell proliferation; MAPK cascade; PI3K–AKT signaling; Wnt signaling; BMP signaling; epithelial-to-mesenchymal transition; nucleotide-excision repair; apoptotic process.
Cell Ontology: primordial germ cell; oogonium; oocyte; ovarian germ cell; tumor cell; peritoneal mesothelial cell; immune cell.
GO cellular components: nucleus, chromatin, chromosome, plasma membrane, receptor tyrosine-kinase complex, mitotic spindle.

5–6. Environment and pathophysiology

The principal causal chain is:

Upstream developmental vulnerability: primordial germ cells undergo migration, imprint erasure, and global epigenetic reprogramming.
Persistence of an immature/pluripotent state: OCT3/4, NANOG, SOX factors, KIT/KITLG, and related programs support survival rather than normal differentiation.
Genomic/epigenomic change: 12p gain, aneuploidy, KIT or RAS activation, PI3K–AKT amplification, imprinting defects, and histology-specific methylation alter proliferation and lineage commitment.
Histologic divergence: germinoma-like cells produce dysgerminoma; endodermal differentiation produces YST; pluripotent somatic differentiation produces teratoma; mixed differentiation produces mixed tumors.
Downstream behavior: rapid proliferation causes a large ovarian mass, pain, rupture/torsion, and peritoneal or nodal dissemination. AFP, β-hCG, and LDH reflect lineage and tumor burden.
Treatment response/resistance: cisplatin DNA adducts normally trigger apoptosis. Resistance can involve nucleotide-excision repair, TP53-pathway change, cancer-stem-cell programs, EMT, and detoxification. OVOL2 overexpression correlates with resistant YST; in NOY1-CR cells, GSTA1, ABCG2, CD133, and ALDH programs were increased. (pinto2023molecularbiologyof pages 16-18, pinto2023molecularbiologyof pages 13-15, pinto2023molecularbiologyof pages 15-16)

Immune involvement is incompletely characterized. Dysgerminomas often contain conspicuous lymphocytes and show immune-pathway epigenetic differences, but no ovarian-specific immune biomarker currently selects checkpoint therapy. Proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, and CRISPR-screen evidence is too sparse for routine annotation. (saani2023clinicalchallengesin pages 8-9, pinto2023molecularbiologyof pages 11-12)

7. Anatomical structures

The primary organ is the ovary—suggested UBERON term ovary (UBERON:0000992)—usually one ovary. Bilaterality occurs in approximately 10–15% of pure dysgerminomas and 5–10% of mixed tumors; bilateral YST and immature teratoma are uncommon. Secondary sites include pelvic and abdominal peritoneum, omentum, retroperitoneal lymph nodes, liver, and lung. (pinto2023molecularbiologyof pages 4-6, saani2023clinicalchallengesin pages 2-3)

Relevant tissues/cells are ovarian parenchyma and germ-cell lineage, with tumor-associated stroma, vasculature, lymphocytes, and peritoneal mesothelium. At subcellular level, the nucleus/chromatin and chromosomes are central because copy-number and epigenetic abnormalities dominate.

8–9. Temporal development, inheritance, and population

MOGCT commonly has acute/subacute presentation and rapid progression, not a long premalignant symptomatic phase. Approximately 60–70% present at an early stage. FIGO ovarian staging is used: stage I is confined to ovaries/fallopian tubes; II involves pelvic extension; III includes extrapelvic peritoneal or retroperitoneal nodal disease; IV denotes distant metastasis. Most relapses occur in the first two years, frequently in peritoneal or retroperitoneal nodal sites. (saani2023clinicalchallengesin pages 3-5, saani2023clinicalchallengesin pages 5-6)

MOGCTs account for approximately 2–5% of ovarian cancers. The 2023 review gives a global incidence near 4 per million women per year; its separate “4 per 100,000” estimate appears internally inconsistent and should not be combined with the per-million estimate without checking the underlying source. Higher proportional frequencies have been reported in Asian and African populations and in Saudi Arabia—13.8% of ovarian tumors versus approximately 5% in Western series—but proportions are affected by the younger population structure and referral patterns. (saani2023clinicalchallengesin pages 2-3, saani2023clinicalchallengesin pages 1-2)

The usual inheritance pattern is sporadic/multifactorial, with no established penetrance, anticipation, carrier frequency, founder variant, or germline-mosaicism model. DSD-associated risk follows the underlying condition—for example, 46,XY gonadal dysgenesis or mosaic Y-chromosome material—not an inheritance pattern intrinsic to MOGCT.

10. Diagnosis

Clinical work-up

A rapidly enlarging adnexal mass in a child or young adult should prompt:

Pelvic/abdominal ultrasonography with Doppler.
Serum AFP, β-hCG, LDH, complete blood count, renal and hepatic function; CA-125 can assist but is nonspecific.
Contrast-enhanced abdominal/pelvic CT or MRI for extent; chest imaging for metastases. PET is selective, not routine.
Fertility and endocrine assessment before treatment where feasible.
Histopathologic confirmation and FIGO staging. (saani2023clinicalchallengesin pages 2-3)

YSTs are often solid or mixed solid-cystic, highly vascular masses. A 2024 cohort described rapid enhancement, rich low-resistance arterial flow, and a “fissure sign,” but these are supportive rather than diagnostic.

Pathology and immunohistochemistry

Useful panels include:

Broad germ-cell marker: SALL4.
Dysgerminoma: OCT3/4, SALL4, SOX17, D2-40, KIT/CD117; typically AFP-negative.
YST: AFP, glypican-3, SALL4; Schiller–Duval bodies and hyaline globules are classic.
Embryonal carcinoma: OCT3/4, SALL4, CD30, cytokeratin.
Choriocarcinoma: β-hCG in syncytiotrophoblast.
Immature teratoma: immature neuroepithelial rosettes/tubules; thorough sampling is essential.

Chromosome-12p FISH may support a malignant postpubertal GCT but is not required in every classic case. (saani2023clinicalchallengesin pages 2-3)

Differential diagnoses include benign mature cystic teratoma, epithelial ovarian carcinoma, sex-cord stromal tumor, small-cell carcinoma of hypercalcemic type, lymphoma, metastatic carcinoma, gestational choriocarcinoma, and pregnancy. Gestational versus nongestational choriocarcinoma may require clinical history and genotyping.

Routine WES/WGS, methylation profiling, or liquid biopsy is not standard. Tumor sequencing is reasonable in relapsed/refractory disease or research protocols; karyotype and targeted DSD testing are indicated when phenotype suggests gonadal dysgenesis. No population screening test exists.

11. Outcomes and prognosis

Early-stage survival is approximately 82–100%; late-stage survival is near 75% in compiled series. Stage I disease has about 90% long-term disease-free survival. Dysgerminoma is exceptionally chemotherapy-sensitive. Adverse factors include advanced stage, residual disease, older/postmenopausal age, YST histology, slow or incomplete tumor-marker decline, platinum resistance, and relapse. Stage IV ovarian GCT in patients aged at least 11 years has been reported to have under 70% long-term disease-free survival. More than half of patients with relapsed YST may die from disease. (saani2023clinicalchallengesin pages 3-5, pinto2023molecularbiologyof pages 16-18, pinto2023molecularbiologyof pages 6-7)

Long-term morbidity is often treatment-related: bleomycin pulmonary toxicity; cisplatin nephrotoxicity, ototoxicity, neuropathy and cardiovascular/metabolic risk; etoposide-related myelosuppression and rare therapy-related leukemia; infertility or premature ovarian insufficiency; and psychosocial/sexual effects.

Fertility outcomes are generally favorable after conservative treatment. One cohort reported pregnancy in 42/45 women, yielding 65 pregnancies and 56 births among 40 survivors; another reported 33 uneventful pregnancies among 31/39 patients. Across studies, 75.6% retained regular menstruation and pregnancy rates ranged from 18.8% to 55.7%, though denominators and attempts to conceive varied. (saani2023clinicalchallengesin pages 3-5, saani2023clinicalchallengesin pages 5-6)

12. Treatment and current applications

Standard algorithm

Stage IA dysgerminoma: unilateral salpingo-oophorectomy (USO), staging, and surveillance. Surgery-only recurrence is approximately 15–25%, but relapse is usually salvageable.
Stage IA grade-1 immature teratoma: USO, staging, surveillance.
Grade 2–3 stage-I immature teratoma: surveillance versus 3–4 cycles BEP remains controversial; pediatric practice is more surveillance-oriented.
Stage-I YST or incompletely staged/marker-positive disease: generally postoperative BEP; surveillance after completely staged, marker-negative disease is investigational and not universally accepted.
Stages II–IV: fertility-sparing cytoreduction when feasible followed by 3–4 cycles BEP. Extensive mutilating surgery should be avoided because of chemosensitivity. EP may be used when bleomycin is unsuitable, particularly in older patients. (saani2023clinicalchallengesin pages 6-8, saani2023clinicalchallengesin pages 5-6, pinto2023molecularbiologyof pages 6-7)

BEP comprises bleomycin, etoposide, and cisplatin. Suggested NCI Thesaurus intervention concepts are unilateral salpingo-oophorectomy, fertility-sparing surgery, tumor-debulking surgery, BEP regimen, EP regimen, active surveillance, and autologous hematopoietic stem-cell transplantation. Chemotherapy agents should also be annotated individually; cisplatin is a platinum coordination compound and etoposide a topoisomerase-II inhibitor.

Relapse and refractory disease

Options include complete resection of operable residual disease and salvage TIP (paclitaxel/ifosfamide/cisplatin), VeIP (vinblastine/ifosfamide/cisplatin), or high-dose TI-CE with autologous stem-cell rescue. Evidence is mostly extrapolated from testicular GCT. Growing teratoma syndrome—enlarging masses during/after chemotherapy with normalized markers and mature teratoma histology—is chemotherapy-resistant and requires complete surgical resection. (saani2023clinicalchallengesin pages 6-8)

Targeted agents remain experimental. Everolimus, imatinib, sunitinib, and pazopanib produced only 0–13% response rates in recurrent GCT series. Brentuximab vedotin produced responses in 2/9 patients. Pembrolizumab and avelumab studies in predominantly male refractory GCT have not shown convincing benefit; these cannot be assumed effective in ovarian disease. (saani2023clinicalchallengesin pages 6-8, saani2023clinicalchallengesin pages 8-9)

Recent trial development

NCT02429687/MOGCT-01, a randomized open-label phase III Chinese study, compares paclitaxel 175 mg/m² plus carboplatin AUC 5–6 every 21 days for 4–6 cycles against BEP for 3–4 cycles. Estimated enrollment is 129; outcomes include five-year progression-free survival, overall survival, response, and toxicity. The registry was updated April 25, 2023 and listed estimated primary completion in May 2025 and completion in 2030. Importantly, the retrieved eligibility field inconsistently described sex-cord stromal histologies despite the title and intervention summary specifying MOGCT; eligibility should therefore be verified directly before referral: https://clinicaltrials.gov/study/NCT02429687. (NCT02429687 chunk 1)

13. Prevention

There is no established primary prevention for sporadic MOGCT, no vaccine, and no population-based ovarian screening program. Secondary prevention consists of rapid evaluation of symptoms and longitudinal marker/imaging surveillance after treatment.

The principal risk-directed primary prevention is prophylactic bilateral gonadectomy for high-risk dysgenetic gonads, especially confirmed 46,XY complete gonadal dysgenesis. In lower-risk DSD groups, timing should be individualized through multidisciplinary endocrine, genetics, gynecology, pathology, fertility, and psychosocial counseling. Ultrasound/MRI cannot reliably exclude early gonadal neoplasia, and no liquid biomarker has sufficient validation to replace histologic risk management. (lu2022gonadaltumorrisk pages 7-8, sowinskaprzepiera2023latediagnosisof pages 1-2)

Tertiary prevention includes fertility counseling and cryopreservation where feasible, pulmonary/renal/auditory monitoring during BEP, avoidance of unnecessary radical surgery, structured surveillance for early relapse, and long-term survivorship care.

14–15. Other species and model systems

No well-validated naturally occurring veterinary disease was found that is sufficiently characterized to serve as a direct homolog of human MOGCT; zoonotic transmission is not applicable. Germ-cell developmental pathways are evolutionarily conserved, but spontaneous ovarian GCTs in companion animals should not be treated as equivalent without comparative pathology and molecular confirmation.

Available experimental systems are limited:

NOY1/NOY2 human ovarian YST cell lines; NOY1-CR was generated by 12 months of stepwise cisplatin exposure and became 22.3-fold more resistant. GSTA1 inhibition restored cisplatin sensitivity.
TC587, derived from a 12-year-old with ovarian YST, expresses AFP and SALL4 and carries NRAS, KIT, KMT2C, RSF1, and TP53 alterations.
Three-dimensional spheroids and quail chorioallantoic-membrane assays model invasion and micrometastasis.
Immunodeficient-mouse xenografts reproduce tumor formation but lack an intact human immune microenvironment.
A pediatric ovarian-YST PDX reportedly mirrored clinical response to bleomycin/etoposide/cisplatin; nevertheless, no broad, well-validated ovarian-GCT PDX panel or organoid biobank exists. (pinto2023molecularbiologyof pages 13-15, pinto2023molecularbiologyof pages 15-16)

These models are useful for cisplatin resistance, stemness, and candidate-drug testing but incompletely capture developmental origin, histologic diversity, host immunity, fertility effects, and patient-to-patient heterogeneity.

Evidence limitations and authoritative interpretation

The most authoritative recent ovarian-specific reviews emphasize that rarity has produced small, retrospective, histologically mixed cohorts and substantial extrapolation from testicular GCT. Apparent genomic frequencies can therefore vary by age and subtype. Molecular findings such as KIT, PI3K, methylation, and miR-371–373 are biologically compelling but are not yet routine predictive biomarkers. The central expert consensus is consequently conservative: preserve fertility whenever oncologically safe, use histology/stage/marker kinetics rather than unvalidated sequencing to guide first-line care, avoid overtreatment of low-risk stage-I disease where surveillance is supported, and refer recurrent disease to a specialist GCT center or clinical trial. (pinto2023molecularbiologyof pages 7-9, pinto2023molecularbiologyof pages 1-3, pinto2023molecularbiologyof pages 16-18)

Principal recent sources

Pinto MT et al. Molecular Biology of Pediatric and Adult Ovarian Germ Cell Tumors: A Review. Cancers. Published May 29, 2023. DOI: https://doi.org/10.3390/cancers15112990. (pinto2023molecularbiologyof pages 4-6)
Saani I et al. Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours. International Journal of Environmental Research and Public Health. Published June 15, 2023. DOI: https://doi.org/10.3390/ijerph20126089. (saani2023clinicalchallengesin pages 3-5)
Lu L et al. Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and Y chromosomal constitution. Frontiers in Pediatrics. Published July 2022. DOI: https://doi.org/10.3389/fped.2022.856128. (lu2022gonadaltumorrisk pages 1-2)
Berek JS et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. International Journal of Gynecology & Obstetrics. Published October 2021. DOI: https://doi.org/10.1002/ijgo.13878. (berek2021cancerofthe pages 17-18)

PMIDs were not reliably exposed in the retrieved full-text metadata and therefore are not fabricated here; DOI URLs are supplied for source resolution.

References

(pinto2023molecularbiologyof pages 4-6): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.
(saani2023clinicalchallengesin pages 2-3): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 87 citations.
(pinto2023molecularbiologyof pages 1-3): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.
(pinto2023molecularbiologyof pages 16-18): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.
(saani2023clinicalchallengesin pages 1-2): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 87 citations.
(saani2023clinicalchallengesin pages 5-6): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 87 citations.
(saani2023clinicalchallengesin pages 3-5): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 87 citations.
(pinto2023molecularbiologyof pages 9-11): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.
(pinto2023molecularbiologyof pages 11-12): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.
(pinto2023molecularbiologyof pages 12-13): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.
(pinto2023molecularbiologyof pages 6-7): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.
(saani2023clinicalchallengesin pages 6-8): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 87 citations.
(NCT02429687 chunk 1): Beihua Kong. TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors. Beihua Kong. 2015. ClinicalTrials.gov Identifier: NCT02429687
(saani2023clinicalchallengesin pages 8-9): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 87 citations.
(pinto2023molecularbiologyof pages 13-15): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.
(pinto2023molecularbiologyof pages 15-16): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.
(NCT02429687 chunk 2): Beihua Kong. TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors. Beihua Kong. 2015. ClinicalTrials.gov Identifier: NCT02429687
(lu2022gonadaltumorrisk pages 6-7): Liangsheng Lu, Feihong Luo, and Xiang Wang. Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and y chromosomal constitution with different genetic etiologies. Frontiers in Pediatrics, Jul 2022. URL: https://doi.org/10.3389/fped.2022.856128, doi:10.3389/fped.2022.856128. This article has 16 citations.
(lu2022gonadaltumorrisk pages 1-2): Liangsheng Lu, Feihong Luo, and Xiang Wang. Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and y chromosomal constitution with different genetic etiologies. Frontiers in Pediatrics, Jul 2022. URL: https://doi.org/10.3389/fped.2022.856128, doi:10.3389/fped.2022.856128. This article has 16 citations.
(lu2022gonadaltumorrisk pages 5-6): Liangsheng Lu, Feihong Luo, and Xiang Wang. Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and y chromosomal constitution with different genetic etiologies. Frontiers in Pediatrics, Jul 2022. URL: https://doi.org/10.3389/fped.2022.856128, doi:10.3389/fped.2022.856128. This article has 16 citations.
(sowinskaprzepiera2023latediagnosisof pages 1-2): Elżbieta Sowińska-Przepiera, Mariola Krzyścin, Adam Przepiera, Agnieszka Brodowska, Ewelina Malanowska, Mateusz Kozłowski, and Aneta Cymbaluk-Płoska. Late diagnosis of swyer syndrome in a patient with bilateral germ cell tumor treated with a contraceptive due to primary amenorrhea. International Journal of Environmental Research and Public Health, 20:2139, Jan 2023. URL: https://doi.org/10.3390/ijerph20032139, doi:10.3390/ijerph20032139. This article has 6 citations.
(piazza2019germcelltumors pages 1-2): Mauri José Piazza and Almir Antonio Urbanetz. Germ cell tumors in dysgenetic gonads. Clinics, 74:e408, Nov 2019. URL: https://doi.org/10.6061/clinics/2019/e408, doi:10.6061/clinics/2019/e408. This article has 37 citations and is from a peer-reviewed journal.
(piazza2019germcelltumors pages 4-5): Mauri José Piazza and Almir Antonio Urbanetz. Germ cell tumors in dysgenetic gonads. Clinics, 74:e408, Nov 2019. URL: https://doi.org/10.6061/clinics/2019/e408, doi:10.6061/clinics/2019/e408. This article has 37 citations and is from a peer-reviewed journal.
(lanciotti2019differentclinicalpresentations pages 3-5): Lucia Lanciotti, Marta Cofini, Alberto Leonardi, Mirko Bertozzi, Laura Penta, and Susanna Esposito. Different clinical presentations and management in complete androgen insensitivity syndrome (cais). International Journal of Environmental Research and Public Health, 16:1268, Apr 2019. URL: https://doi.org/10.3390/ijerph16071268, doi:10.3390/ijerph16071268. This article has 126 citations.
(pinto2023molecularbiologyof pages 7-9): Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, and Luiz Fernando Lopes. Molecular biology of pediatric and adult ovarian germ cell tumors: a review. Cancers, 15:2990, May 2023. URL: https://doi.org/10.3390/cancers15112990, doi:10.3390/cancers15112990. This article has 24 citations.
(lu2022gonadaltumorrisk pages 7-8): Liangsheng Lu, Feihong Luo, and Xiang Wang. Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and y chromosomal constitution with different genetic etiologies. Frontiers in Pediatrics, Jul 2022. URL: https://doi.org/10.3389/fped.2022.856128, doi:10.3389/fped.2022.856128. This article has 16 citations.
(berek2021cancerofthe pages 17-18): Jonathan S. Berek, Malte Renz, Sean Kehoe, Lalit Kumar, and Michael Friedlander. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. International Journal of Gynaecology and Obstetrics, 155:61-85, Oct 2021. URL: https://doi.org/10.1002/ijgo.13878, doi:10.1002/ijgo.13878. This article has 726 citations.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Classifications

Definitions

Subtypes

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Diagnosis

Progression

Prevalence

Differential Diagnoses

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

Malignant Germ Cell Tumor of the Ovary: Disease-Characteristics Report

Executive summary

1. Disease information

Definition and classification

Identifiers and synonyms

2. Etiology, risk, and protective factors

Causal framework

Established genetic/developmental risk

Environmental, lifestyle, infectious, and protective factors

3. Phenotypes

4. Genetic and molecular information

Somatic alterations

Epigenetics, transcriptomics, and noncoding RNA

Suggested annotations

5–6. Environment and pathophysiology

7. Anatomical structures

8–9. Temporal development, inheritance, and population

10. Diagnosis

Clinical work-up

Pathology and immunohistochemistry

11. Outcomes and prognosis

12. Treatment and current applications

Standard algorithm

Relapse and refractory disease

Recent trial development

13. Prevention

14–15. Other species and model systems

Evidence limitations and authoritative interpretation

Principal recent sources

Artifacts